US20110230562A1 - Melanins synthesized chemically or via enzyme catalysis - Google Patents
Melanins synthesized chemically or via enzyme catalysis Download PDFInfo
- Publication number
- US20110230562A1 US20110230562A1 US12/809,369 US80936908A US2011230562A1 US 20110230562 A1 US20110230562 A1 US 20110230562A1 US 80936908 A US80936908 A US 80936908A US 2011230562 A1 US2011230562 A1 US 2011230562A1
- Authority
- US
- United States
- Prior art keywords
- melanin
- acid
- melanins
- group
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004190 Enzymes Human genes 0.000 title description 12
- 108090000790 Enzymes Proteins 0.000 title description 12
- 238000006555 catalytic reaction Methods 0.000 title 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 163
- 238000000034 method Methods 0.000 claims description 64
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 44
- 241000700605 Viruses Species 0.000 claims description 40
- -1 hydroxynapthalene Chemical compound 0.000 claims description 34
- 102000030523 Catechol oxidase Human genes 0.000 claims description 32
- 108010031396 Catechol oxidase Proteins 0.000 claims description 32
- 230000000840 anti-viral effect Effects 0.000 claims description 28
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 claims description 26
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 23
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 23
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 23
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 22
- 235000004883 caffeic acid Nutrition 0.000 claims description 22
- 229940074360 caffeic acid Drugs 0.000 claims description 22
- 239000002243 precursor Substances 0.000 claims description 22
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallyl group Chemical group C1(=C(C(=CC=C1)O)O)O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 17
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 16
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 15
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 13
- 229940015301 baicalein Drugs 0.000 claims description 13
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- 208000037797 influenza A Diseases 0.000 claims description 10
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 claims description 9
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 8
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 8
- 235000005487 catechin Nutrition 0.000 claims description 8
- 229950001002 cianidanol Drugs 0.000 claims description 8
- NGKZFDYBISXGGS-UHFFFAOYSA-N epinine Chemical compound CNCCC1=CC=C(O)C(O)=C1 NGKZFDYBISXGGS-UHFFFAOYSA-N 0.000 claims description 8
- 229940074391 gallic acid Drugs 0.000 claims description 8
- 235000004515 gallic acid Nutrition 0.000 claims description 8
- 229940079877 pyrogallol Drugs 0.000 claims description 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 7
- 206010061592 cardiac fibrillation Diseases 0.000 claims description 7
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical group C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 7
- 230000002600 fibrillogenic effect Effects 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 241001529453 unidentified herpesvirus Species 0.000 claims description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 6
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 6
- 208000001490 Dengue Diseases 0.000 claims description 6
- 206010012310 Dengue fever Diseases 0.000 claims description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 6
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 208000025729 dengue disease Diseases 0.000 claims description 6
- 229960005139 epinephrine Drugs 0.000 claims description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 6
- JRNGUTKWMSBIBF-UHFFFAOYSA-N naphthalene-2,3-diol Chemical compound C1=CC=C2C=C(O)C(O)=CC2=C1 JRNGUTKWMSBIBF-UHFFFAOYSA-N 0.000 claims description 6
- 229960002748 norepinephrine Drugs 0.000 claims description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001285 quercetin Drugs 0.000 claims description 6
- 235000005875 quercetin Nutrition 0.000 claims description 6
- CRPNQSVBEWWHIJ-UHFFFAOYSA-N 2,3,4-trihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C(O)=C1O CRPNQSVBEWWHIJ-UHFFFAOYSA-N 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims description 5
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 claims description 5
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 5
- 201000003740 cowpox Diseases 0.000 claims description 5
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 claims description 5
- 208000007089 vaccinia Diseases 0.000 claims description 5
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 4
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 4
- 241000589562 Brucella Species 0.000 claims description 4
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 4
- 241000223935 Cryptosporidium Species 0.000 claims description 4
- 241000711950 Filoviridae Species 0.000 claims description 4
- 241000186781 Listeria Species 0.000 claims description 4
- 241001295810 Microsporidium Species 0.000 claims description 4
- 241001263478 Norovirus Species 0.000 claims description 4
- 241000709664 Picornaviridae Species 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 241000606701 Rickettsia Species 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000688 bacterial toxin Substances 0.000 claims description 4
- 229930016911 cinnamic acid Natural products 0.000 claims description 4
- 235000013985 cinnamic acid Nutrition 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- VZBNZFYHLQRFPS-UHFFFAOYSA-N 2-(6,7-dihydroxy-2-oxochromen-4-yl)acetic acid Chemical compound C1=C(O)C(O)=CC2=C1OC(=O)C=C2CC(=O)O VZBNZFYHLQRFPS-UHFFFAOYSA-N 0.000 claims description 3
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000004700 cobalt complex Chemical class 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims 3
- 208000037798 influenza B Diseases 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- ABFVFIZSXKRBRL-UHFFFAOYSA-N 2-hydroxy-2-phenyl-3h-chromen-4-one Chemical compound C1C(=O)C2=CC=CC=C2OC1(O)C1=CC=CC=C1 ABFVFIZSXKRBRL-UHFFFAOYSA-N 0.000 claims 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 claims 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000004698 iron complex Chemical class 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 abstract description 12
- 238000003786 synthesis reaction Methods 0.000 abstract description 11
- 230000008099 melanin synthesis Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 65
- 239000000758 substrate Substances 0.000 description 54
- 239000000203 mixture Substances 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 33
- 229920000642 polymer Polymers 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 230000036515 potency Effects 0.000 description 21
- 230000007935 neutral effect Effects 0.000 description 19
- 239000000843 powder Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 235000013824 polyphenols Nutrition 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 230000000007 visual effect Effects 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 14
- 229960004150 aciclovir Drugs 0.000 description 13
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 208000031886 HIV Infections Diseases 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 238000002211 ultraviolet spectrum Methods 0.000 description 9
- 102000016943 Muramidase Human genes 0.000 description 8
- 108010014251 Muramidase Proteins 0.000 description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 238000002389 environmental scanning electron microscopy Methods 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229960000274 lysozyme Drugs 0.000 description 8
- 239000004325 lysozyme Substances 0.000 description 8
- 235000010335 lysozyme Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 7
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 5
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 150000004053 quinones Chemical class 0.000 description 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 240000008790 Musa x paradisiaca Species 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000003622 anti-hsv Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229930001119 polyketide Natural products 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- 229940082044 2,3-dihydroxybenzoic acid Drugs 0.000 description 2
- GMGIWEZSKCNYSW-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;dihydrate Chemical compound O.O.C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 GMGIWEZSKCNYSW-UHFFFAOYSA-N 0.000 description 2
- OZNMEZAXFKUCPN-UHFFFAOYSA-N 3,5,7-trihydroxychromen-4-one Chemical compound O1C=C(O)C(=O)C=2C1=CC(O)=CC=2O OZNMEZAXFKUCPN-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108020001991 Protoporphyrinogen Oxidase Proteins 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 208000001203 Smallpox Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Natural products C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 235000005513 chalcones Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 201000006061 fatal familial insomnia Diseases 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 2
- 230000003101 melanogenic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 201000000317 pneumocystosis Diseases 0.000 description 2
- 229920013637 polyphenylene oxide polymer Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 208000008864 scrapie Diseases 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- FTVWIRXFELQLPI-CYBMUJFWSA-N (+)-Naringenin Natural products C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- OFUMQWOJBVNKLR-NQQJLSKUSA-N (+)-catechin monohydrate Chemical compound O.C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 OFUMQWOJBVNKLR-NQQJLSKUSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- SQDZFVQVNYCATP-UHFFFAOYSA-N 2-(2-oxochromen-6-yl)acetic acid Chemical compound O1C(=O)C=CC2=CC(CC(=O)O)=CC=C21 SQDZFVQVNYCATP-UHFFFAOYSA-N 0.000 description 1
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZFCWURBGTORKKO-UHFFFAOYSA-N 3,4-dihydroxychromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C(O)=C2O ZFCWURBGTORKKO-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- KDHUXRBROABJBC-UHFFFAOYSA-N 4-Aminocatechol Chemical compound NC1=CC=C(O)C(O)=C1 KDHUXRBROABJBC-UHFFFAOYSA-N 0.000 description 1
- DMZOKBALNZWDKI-JBNLOVLYSA-N 4-Coumaroyl-CoA Natural products S(C(=O)/C=C/c1ccc(O)cc1)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@@](=O)(O[P@@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C DMZOKBALNZWDKI-JBNLOVLYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- GPDJGLOROGNHJD-UHFFFAOYSA-N 5,6,7-trihydroxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1C(=O)C=2C(O)=C(O)C(O)=CC=2OC1C1=CC=CC=C1 GPDJGLOROGNHJD-UHFFFAOYSA-N 0.000 description 1
- NWQBYMPNIJXFNQ-UHFFFAOYSA-N 7,8-dihydroxy-4-methyl-1-benzopyran-2-one Chemical compound OC1=C(O)C=CC2=C1OC(=O)C=C2C NWQBYMPNIJXFNQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- 0 CC1=C(O)C2=C(C=C1)C(=O)C1=CC=CC=C1C2=O.CC1=C(O)C=CC=C1.OC1=C(O)C=C2OcccC2=C1 Chemical compound CC1=C(O)C2=C(C=C1)C(=O)C1=CC=CC=C1C2=O.CC1=C(O)C=CC=C1.OC1=C(O)C=C2OcccC2=C1 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000250507 Gigaspora candida Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000713673 Human foamy virus Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-Tyrosine Natural products OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 206010073245 Meningitis aspergillus Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000234295 Musa Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- QKTAFNAZTCSZGF-UHFFFAOYSA-N OC(=O)C1=CC=C(O)C=C1O.OC(=O)C1=CC=C(O)C=C1O Chemical compound OC(=O)C1=CC=C(O)C=C1O.OC(=O)C1=CC=C(O)C=C1O QKTAFNAZTCSZGF-UHFFFAOYSA-N 0.000 description 1
- MMOPREBWKCZVPO-ZIKNSQGESA-N OC(=O)C=CC1=CC=C(O)C=C1.OC(=O)\C=C\C1=CC=C(O)C=C1 Chemical compound OC(=O)C=CC1=CC=C(O)C=C1.OC(=O)\C=C\C1=CC=C(O)C=C1 MMOPREBWKCZVPO-ZIKNSQGESA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 208000001449 Viral Hemorrhagic Septicemia Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- TUCIXUDAQRPDCG-UHFFFAOYSA-N benzene-1,2-diol Chemical compound OC1=CC=CC=C1O.OC1=CC=CC=C1O TUCIXUDAQRPDCG-UHFFFAOYSA-N 0.000 description 1
- HUFIRBOBXZUFPV-UHFFFAOYSA-N benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1.OC1=CC=CC(O)=C1 HUFIRBOBXZUFPV-UHFFFAOYSA-N 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 229950009494 bropirimine Drugs 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- VZHHNBNSMNNUAD-UHFFFAOYSA-N cobalt 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical group [Co].OC1=CC=CC=C1C=NCCN=CC1=CC=CC=C1O VZHHNBNSMNNUAD-UHFFFAOYSA-N 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960003157 epinephrine bitartrate Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000035557 fibrillogenesis Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- LTYOQGRJFJAKNA-VFLPNFFSSA-N malonyl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-VFLPNFFSSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000002815 nickel Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 229940042443 other antivirals in atc Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 108700018720 recombinant interferon alpha 2b-like Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- DMZOKBALNZWDKI-MATMFAIHSA-N trans-4-coumaroyl-CoA Chemical compound O=C([C@H](O)C(C)(COP(O)(=O)OP(O)(=O)OC[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2N=C1)OP(O)(O)=O)C)NCCC(=O)NCCSC(=O)\C=C\C1=CC=C(O)C=C1 DMZOKBALNZWDKI-MATMFAIHSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention provides the chemical and enzyme-catalyzed synthesis of melanins.
- the synthesized melanins inhibit the binding of viruses to animal cells, prevent a virus from infecting the cells of its host, and prevent the spread of viral infections from person-to-person.
- Melanin is a general term for a group of high molecular weight black and brown pigments that arise from the oxidation and polymerization of polyphenols and aromatic amino acids (Prota, G., Melanins and Melanogenesis. 1992, San Diego: Academic Press, Inc. 1-290; Riley, P. A., Int. J. Biochem. Cell Biol. (1997) 29(11):1235-1239).
- Melanins are normal constituents of animal and plant tissues and are also present in many microorganisms. Melanins contribute to the coloration of the skin and hair of animals, the seeds, berries, flowers, and leaves of plants and to subcellular structures in certain bacteria and fungi.
- Melanins are typically identified by their unique physicochemical properties including their solubility characteristics, their tendency to aggregate in the presence of metal ions, their characteristic adsorption spectra in the UV and infrared regions, their ability to act as semi-conductors, their decolorization by strong oxidizing agents, their antioxidant and radioprotective properties, and their resistance to hydrolysis under strongly acidic and strongly basic conditions. Natural and enzymatically synthesized melanins exhibit strong absorption throughout the UV and visible regions. Published spectra are characterized by a monotonic increase in the absorbance with decreasing wavelengths with a barely detectable shoulder between 290 and 320 nm.
- the infrared spectra of melanins show absorption bands expected for an aromatic or a heteroaromatic system of OH, NH, and conjugated carbonyl groups.
- Recent analyses of a natural melanin from Sepia officinalis using a combination of scanning electron microscopy, atomic force microscopy, x-ray scattering, and mass spectrometry are consistent with the notion that natural melanins are comprised of small oligomeric units that aggregate to form stable filaments, particles (5-200 nm in diameter) and aggregates of the particles (Clancy, C. M. et al., Biochemistry (2001) 40 (44):13353-13360).
- the bulk of the scientific literature on melanin structure and function pertains to the mammalian melanins. Considerably less is known about the plant-derived melanins even though they are an abundant constituent of the biomass.
- the biosynthesis of plant melanins is catalyzed by a family of Type III polyketide synthetases (e.g., chalcone synthetase) which catalyze the first committed step in the synthesis of a large number of biologically important flavonoids and phytoalexins.
- the PKS III enzymes utilize a starter CoA-ester (e.g., p-coumaroyl-CoA) from the phenylpropanoid pathway and catalyze three sequential condensation reactions with an extender CoA-ester (e.g., malonylCoA). This is followed by a ring closure, and an aromatization to form chalcones (e.g., naringenin).
- chalcones e.g., naringenin
- Many different aromatic phenolics can be made by this mechanism depending on which polyketide synthetase is present and which of the many possible starter and extender CoA-esters are available for incorporation.
- the aromatic phenols and polyphenols that are the products of the polyketide pathway in a particular plant are oxidized to quinones by the enzyme polyphenol oxidase.
- the quinones are then joined together by free radical polymerization reactions to form oligomers that contain a mixture of quinone, hydroquinone, and semi-quinone functional groups.
- the oligomers associate to form stable, non-covalent complexes that take the form of particles, aggregates of particles, and fibers and exhibit the distinctive physical and chemical characteristics of the natural melanins.
- Banister et al. U.S. Pat. No. 6,303,106 describes the enzymatic production of melanins from phenolic compounds and an enzyme selected from tyrosinase, laccase and peroxidase. The produced melanins are used in the production of cosmetics.
- Synthetic melanins have been shown to have activity against HIV infections in in vitro cell culture models (Novikov, 2001; Garger, U.S. Pat. No. 6,440,691).
- the intrathecal administration of synthetic and natural melanins has been proposed as a treatment for certain neurodegenerative diseases, however evidence for their effectiveness has yet to be presented (Berliner, U.S. Pat. No. 5,817,631).
- the present invention provides a method for producing a melanin comprising the step of: (a) contacting an oxidase and a phenolic substrate containing at least two hydroxyl groups for a time sufficient to produce a melanin.
- the method can optionally further comprise any of the following steps: (b) inactivating the oxidase, (c) precipitating the melanin, and/or (d) purifying the melanin.
- the present invention further provides a melanin produced by the step of (a) contacting (1) an oxidase and (2) at least one phenolic substrate with at least two hydroxyl groups for a time sufficient to produce a melanin.
- the method of the present invention can be used to produce novel homologous (single PPO substrate) and heterologous (two or more PPO substrates) melanins, including enzymatically synthesized melanins comprising bicyclic dihydroxyphenolic monomers.
- the present disclosure also provides a method for the chemical synthesis of a melanin.
- the method comprises the step of: (a) contacting a phenolic substrate and a catalyst for a time sufficient to produce a melanin.
- the method can optionally further comprise the step of: (b) purifying the melanin.
- the substrate contains two or more aromatic hydroxyl-groups.
- the present invention includes novel enzymatically and chemically synthesized melanins, including those prepared from cinnamic acid and those prepared from coumarin.
- the melanins of the present invention are typically water soluble.
- the present invention further provides antiviral compositions, especially compositions suitable for intravaginal, intrarectal, or topical use.
- the enzymatically and chemically synthesized melanins of the present invention can be used to prevent infections, especially those that are caused by enveloped viruses, and those which are sexually transmitted.
- FIG. 1 is a HPLC-GPC chromatogram of enzymatically synthesized caffeic acid melanin (“ES-CAM”) and non-enzymatically synthesized caffeic acid melanin.
- ES-CAM prepared by the enzymatic process described in this disclosure (A) and caffeic acid melanin prepared by a nonenzymatic synthesis procedure (B) were analyzed by HPLC on a column of BioSep SEC-S2000.
- the mobile phase 0.05 M sodium borate, pH 8.6, was pumped at a flow rate of 0.75 mL/min.
- Compounds in the effluent were detected by their absorbances at 220 nm using a diode array detector.
- the column was calibrated with polymer standards of known molecular weights to enable the estimation of molecular weight based on retention time.
- FIG. 2 is a HPLC-GPC chromatogram of enzymatically synthesized esculetin melanin (“ES-EM”) and nonenzymatically-synthesized esculetin melanin ES-EM prepared by the process described in this disclosure (A) and nonenzymatically synthesized esculetin melanin (B) were analyzed as described in the legend to FIG. 1 .
- ES-EM enzymatically synthesized esculetin melanin
- A enzymatically synthesized esculetin melanin
- B nonenzymatically synthesized esculetin melanin
- FIG. 3 is the absorbance spectra of ES-CAM and ES-EM and their nonenzymatically synthesized analogues.
- the UV spectra at the retention times corresponding to the peaks labeled in FIGS. 1 and 2 were recorded with a diode array detector.
- FIG. 4 is the FTIR spectra of ES-CAM and ES-EM.
- ES-CAM or ES-EM were lyophilized and ground into a powder.
- a sample of the dry solid was pressed on to the surface of polished potassium bromide salt plate and analyzed using a Thermo-Nicolet Nexus FTIR bench and a Continuum microscope with an MCT detector.
- the spectra were collected at 8 cm ⁇ 1 resolution.
- FIG. 5 is a MALDI-TOF mass spectrum of ES-EM.
- ES-EM was diluted with a matrix consisting of 10 mg/mL, DHBA in ethanol/water ITF A, 50/50/0.1 (v/v/v), spotted on a gold target, and analyzed with a Ciphergen PBS II mass spectrometer.
- the spectrometer was operated in the positive ion mode at a laser intensity of 240 and a sensitivity of 6.
- FIG. 6 a is the HPLC-GPC chromatograms and UV spectra of chemically synthesized melanins C1-C6. The compounds are listed in table 4.
- FIG. 6 b is the HPLC-GPC chromatograms and UV spectra of chemically synthesized melanins C7-C12. The compounds are listed in table 4.
- FIG. 6 c is the HPLC-GPC chromatograms and UV spectra of chemically synthesized melanins C13-C18. The compounds are listed in table 4.
- FIGS. 7 a is the FTIR spectra of chemically synthesized melanins C1, C2, C4, and C9.
- FIGS. 7 b are the FTIR spectra of chemically synthesized melanins C10, C11, C12, and C17.
- FIG. 8 illustrates the effect of the synthetic melanins ES-EM, C11, and C12 on Lysozyme Fibrillation in vitro.
- the present invention provides a method for producing a melanin comprising the step of: (a) contacting a polyphenol oxidase (PPO) and a pyrocatechol substrate for a time sufficient to produce a melanin.
- the method can optionally further comprise any of the following steps: (b) inactivating the oxidase, (c) precipitating the melanin, and/or (d) purifying the melanin.
- the PPO and pyrocatechol substrate are contacted for at least 6 hours, preferably at least 12 hours, more preferably at least 24 hours.
- the enzymatic reaction is typically conducted in aqueous media, at a neutral pH, and at least at room temperature.
- the reaction can be terminated by inactivating the PPO either chemically, by altering the pH of the reaction (for example, by adding base or acid), or physically (by heating or cooling the reaction).
- Melanin can be purified from the reaction mixture by precipitation (as described below in the examples), centrifugation, chromatography and other well known methods.
- PPOs can be isolated from mammalian, plant and fungal sources.
- Exemplary PPOs include banana and mushroom PPO enzyme and tyrosinases from various sources.
- mushroom PPO enzyme is used. Any activity of enzyme can be used.
- the substrates of the present invention are pyrocatechol substrates. In some cases, tri-hydroxyl benzene substrates can be used.
- the pyrocatechol substrates of the present invention typically have one of the following cores:
- These cores can have one or more substituents including hydroxyl, amino, thiol, carbonyl, unsubstituted or substituted alkyl, unsubstituted or substituted-8-carbocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclyl, and unsubstituted or substituted heteroaryl.
- substituents including hydroxyl, amino, thiol, carbonyl, unsubstituted or substituted alkyl, unsubstituted or substituted-8-carbocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclyl, and unsubstituted or substituted heteroaryl.
- one or none of the dashed lines can be a double bond.
- Other cores can also be used.
- the pyrocatechol substrate is a bicyclic compound such as esculetin, dapthnetin, catechin, baicalein or alizarin.
- the pyrocatechol substrate is a monocyclic compound.
- Exemplary pyrocatechol substrates useful in the present invention are shown below in Table 1.
- Exemplary phenolic substrates include dopamine, L-DOPA, catechin hydrate, pyrocatechol, protocatechuric acid, serotonin, DOPAC, deoxyepinephrine, isoproterenol, norepinephrine, epinephrine bitartrate, baicalein, 2,3-dihydroxybenzoic acid, esculetin, 2,3,4-trihydroxybenzoic acid, quercetin, gallic acid, 2,3,4-trihydroxybenzaldehyde, alizarin, 2,3-dihydroxynapthalene, pyrogallol, caffeic acid, nordihydroguaiaretic acid, daphnetin, phenol red, and 4-methyl daphnetin.
- the phenolic substrate is selected from the group consisting of dopamine, L-DOPA, caffeic acid, protocatechuric acid, DOPAC, deoxyepinephrine, gallic acid or pyrogallol.
- an initial amount of PPO substrate can be coupled to a solid phase. Thereafter the polymerization reaction can be conducted in solution by exposing the solid phase to enzyme and further PPO substrate. In this way, the formed melanin can be easily manipulated and isolated.
- Enzymatically synthesized melanins prepared by this invention are generally found to be soluble in aqueous solutions at pH's that are within the physiological range for humans and other animal species.
- Enzymatically synthesized melanins prepared by this invention typically are composed of 50 to 200 substrate monomers. These melanins are typically aggregates of oligomers with different degrees of polymerization.
- the enzymatically synthesized melanin is prepared from the phenolic substrate caffeic acid.
- Such melanins are water-soluble, and are composed of oligomers with molecular weights in the range of approximately 1.2 to 5.4 kDa which, in turn, aggregate in aqueous solution to form complexes with a number average molecular weight of approximately 19.7 kDa.
- the enzymatically synthesized melanin is prepared from the phenolic substrate esculetin.
- Such melanins are water-soluble and are composed of oligomers with molecular weights in the range of approximately 1.0 to 5.0 kDa which, in turn, aggregate in aqueous solution to form complexes with a number average molecular weight of approximately 15.4 kDa.
- Enzymatically synthesized melanins prepared according to this invention are water soluble polymers of sufficient molecular weight to be nondialyzable through standard dialysis membranes with molecular weight cutoffs in the range of 10 to 13 kDa.
- the enzymatically synthesized melanins precipitate at pH's of less than 4.5.
- These enzymatically synthesized melanins typically have ultraviolet absorbance spectra that are characterized by steep increases in absorbance as the excitation wavelength decreases from 300 to 200 nm.
- Such melanins typically have FTIR spectra that demonstrate strong absorption bands in at least some of the following regions: at approximately 3400 cm ⁇ 1 ; in the 1600 to 1700 cm ⁇ 1 range; in the 1500 to 1600 cm ⁇ 1 range; in the 1360 to 1410 cm ⁇ 1 ; and in the 1220 to 1280 cm ⁇ 1 range.
- Enzymatically synthesized melanins prepared according to this invention typically have positive ion MALDI TOF mass spectra that show partially resolved distributions of singly-charged pseudo-molecular ions between approximately 1000 and 5400 m/z units.
- the present disclosure also provides a method for the chemical synthesis of a melanin.
- the method comprises the step of: (a) contacting a phenolic substrate and a catalyst for a time sufficient to produce a melanin.
- the method can optionally further comprise the step of: (b) purifying the melanin.
- the substrate contains two or more aromatic hydroxyl-groups.
- the reaction is typically conducted in aqueous media, at a basic pH and at an elevated temperature.
- the resulting melanin can be purified from the reaction mixture by dialysis, chromatography and other well know methods.
- the examples of the catalyst include iron, cobalt and nickel complexes.
- the preferred example is N,N′-bis(salicylidene)ethylenediaminocobalt (II) (salcomine).
- Exemplary substrates include pyrogallol, quercetin dihydrate, daphnetin, 2,3-dihydroxynapthalene, 3,4 dihydroxybenzoic acid (protocatechuric acid), 6,7-dihydroxy-4-coumarinyl acetic acid, baicalein, gallic acid, 3,4-dihydroxyphenylacetic acid, esculetin, caffeic acid, catechin, nordihydroquaiuretic acid, baicalein hydrate, 2,3,4-trihydroxybenzoic acid, epinephrine (bitartrate), epinine (2-deoxy norepinephrine), and 2,3,4-trihydroxybenzaldehyde.
- 18 homopolymers were synthesized using the 18 different precursors, listed in Table 4.
- the chemically synthesized polymers are highly water-soluble compared to catecholamine-derived synthetic melanins and natural melanins derived from Sepia or human hair.
- the products are stable as dry powders (possibly indefinitely).
- the synthetic polymers are likely to be structurally unique polymers that have not been previously described, and may also serve as lead compounds for the development of derivatives that may have additional unique and useful activities or applications.
- Synthetic melanins can be used as components of multi-agent prophylaxis or treatment regimens in which multiple mechanisms of microbial infection are simultaneously targeted.
- the melanins made using this process are active against many different viruses including HIV, HSV 1, and HSV 2, CMV, VZV, Influenzas A and B, SARS, Vaccinia, Cowpox, RSV, Tacaribe, Dengue, and Rift Valley Fever, and have low toxicities toward animal cells. They may be used as for the prevention of diseases such as herpes and AIDS in humans as well as diseases caused by a number of different enveloped viruses that infect insects, crustaceans, fish, cattle, poultry and other animal species.
- This method represents the first demonstration of the generalizability of a rational chemical synthetic process for the production of synthetic melanins from a wide variety of dihydroxyphenol-containing compounds.
- the combination of buffer-regulated, moderately basic pH and a cobalt complex (such as salcomine) enables the formation of reactive para-quinones, and molecular oxygen into a process for the synthesis.
- the synthetic approach may be used to prepare homo- or hetero-polymers from many different hydroxyphenol-containing substrates, and also makes it possible to incorporate mono-hydroxylphenols into synthetic homo- or hetero-polymers analogs.
- the process is scalable and provides reasonable yields of products.
- Melanins of the present invention can be formulated into compositions by the addition of a pharmaceutically acceptable carrier.
- suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
- the pharmaceutically acceptable carriers described herein for example, vehicles, adjuvants, excipients, or diluents, are well-known to those who are skilled in the art.
- the pharmaceutically acceptable carrier is chemically inert to the active compounds and has no detrimental side effects or toxicity under the conditions of use.
- the pharmaceutically acceptable carriers can include polymers and polymer matrices.
- the compounds of the invention may be administered topically to the skin or mucosa, either dermally or transdermally.
- Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used.
- Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
- Penetration enhancers may be incorporated (for example, as described in Finnin and Morgan, J. Pharm. Sci., 88(10): 955-958 (October 1999)).
- Other means of topical administration include delivery by iontophoresis, electroporation, phonophoresis, sonophoresis and microneedle or needle-free injection.
- the melanin can be administered orally in solid dosage forms, such as lozenges, capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, mouthwashes and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.
- the melanin can also be administered intranasally (nose drops) or by inhalation of a drug powder mist.
- Other dosage forms are potentially possible such as, administration transdermally, via patch mechanism or ointment.
- the melanin can be administered employing a sustained or delayed release delivery system or an immediate release delivery system.
- Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the melanin, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions.
- Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, propylene glycol, glycerin, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
- diluents such as water and alcohols, for example, ethanol, benzyl alcohol, propylene glycol, glycerin, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
- Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch.
- Tablet forms can include one or more of the following: lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
- Lozenge forms can comprise the melanin in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the melanin in an inert base, such as gelatin and glycerin, or sucrose and acadia, emulsions, and gels containing, in addition to the melanin, such carriers as are known in the art.
- an inert base such as gelatin and glycerin, or sucrose and acadia, emulsions, and gels containing, in addition to the melanin, such carriers as are known in the art.
- the compounds of the present invention can be made into aerosol formulations to be administered via inhalation.
- aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, and nitrogen. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- the compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, such as poly(ethyleneglycol) 400, glycerol ketals, such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adj
- Oils which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
- Suitable soaps for use in parenteral formulations include fatty acid alkali metal, ammonium, and triethanolamine salts
- suitable detergents include (a) cationic detergents such as, for example, dimethyldialkylammonium halides, and alkylpyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-aminopropionates, and 2-alkylimidazoline quaternary ammonium salts, and (e) mixtures thereof.
- cationic detergents such as, for
- the parenteral formulations typically contain from about 0.5% to about 25% by weight of the melanin in solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5% to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
- HLB hydrophile-lipophile balance
- compositions of the present invention are also well-known to those who are skilled in the art. The choice of excipient will be determined in part by the particular compound, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical composition of the present invention. The following methods and excipients are merely exemplary and are in no way limiting.
- the pharmaceutically acceptable excipients preferably do not interfere with the action of the melanins and do not cause adverse side-effects.
- Suitable carriers and excipients include solvents such as water, alcohol, and propylene glycol, solid absorbants and diluents, surface active agents, suspending agent, tableting binders, lubricants, flavors, and coloring agents.
- the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
- sterile liquid excipient for example, water
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
- the requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, J. B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, Eds., 238-250 (1982) and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., 622-630 (1986).
- the melanins of the present invention can be formulated as:
- Coatings on medical grade substrates for example, dressings, packings, meshes, films, filtering surfaces, filters, infusers, fibers such as dental floss or sutures, containers or vials, from materials composed of, for example, polyethylene, high density polyethylene, polyvinylchloride, latex, silicone, cotton, rayon, polyester, nylon, cellulose, acetate, carboxymethylcellulose, alginate, chitin, chitosan and hydro fibres;
- bioabsorbable and/or hygroscopic substrates such as: synthetic bioabsorbable polymers (for example polyesters/polylactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., polyanhydrides, polyesteramides, polyorthooesters, polyphosphazenes, and copolymers of these and related polymers or monomers) or naturally derived polymers (for example, proteins such as albumin, fibrin, collagen, elastin; polysaccharides such as chitosan, alginates, hyaluronic acid; acellular matrix materials such as small intestinal submucosa; and biosynthetic polyesters such as 3-hydroxybutyrate polymers);
- synthetic bioabsorbable polymers for example polyesters/polylactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate
- Occlusions or hydrated dressings in which the dressing is impregnated with a powder or solution, or is used with a topical formulation, with such dressings for example as hydrocolloids, hydrogels, polyethylene, polyurethane, polvinylidine, siloxane or silicone dressings;
- Gels formulated with powders or solutions of the melanins with such materials as hydrocolloid powders such as carboxymethylcellulose, alginate, chitin, chitosan and hydro fibres, together with such ingredients as preservatives, pectin and viscosity enhancers;
- Liquids formulated as solutions, dispersions, or suspensions, by dissolving coatings or powders of the melanins, for example as topical solutions, aerosols, mists, sprays, drops, infusions and instillation solutions for body cavities and tubes such as the bladder, prostate, perineal, pleural, intestinal and alimentary canal;
- Formulations suitable for administration to the nasal membranes, the oral cavity or to the gastrointestinal tract formulated with powders or liquids of the melanins in such forms as lozenges, toothpastes, gels, powders, coated dental implants, dental floss or tape, chewing gum, wafers, mouth washes or rinses, drops, sprays, elixirs, syrups, tablets, or capsules;
- Formulations suitable for vaginal or rectal administration formulated with powders or liquids of the melanin formulated in or coated on such forms as suppositories, dressings, packings, condoms, tampons, diaphragms, creams, gels, ointments, pastes, foams, sprays, and solutions for retention enemas or instillations.
- Transvaginal drug delivery is a well known means of administering drugs to a female (Woolfson, A. D., Malcolm, R. K. and Gallagher, R. (2000) Critical Reviews in Therapeutic Drug Carrier Systems, 17:509 555).
- transvaginal drug delivery systems include mucoadhesive gels and hydrogels (such as weakly crosslinked polymers which are able to swell in contact with water and spread onto the surface of mucus); vaginal tablets (formulated with mucoadhesive polymers in order to increase intravaginal residence time); vaginal pessaries and suppositories (such as natural gums, fatty acids, alum and rock salts); microspheres for the delivery of peptide and protein drugs; and intravaginal rings (torus-shaped polymeric devices designed to release one or more incorporated substances in a controlled fashion). Additionally, formulations suitable for rectal administration may be presented as suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.
- bases such as emulsifying bases or water-soluble bases.
- Melanins of the present invention can be used for either prevent or treatment of viral diseases.
- HIV disease refers to a well recognized constellation of signs and symptoms (including the development of opportunistic infections) in persons who are infected by an HIV virus, as determined by antibody or western blot studies. Laboratory findings associated with this disease are a progressive decline in T-helper cells.
- the dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the animal over a reasonable time frame.
- dosage will depend upon a variety of factors including a condition of the animal, the body weight of the animal, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, etc.
- the size of the dose also will be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of the compound and the desired physiological effect.
- a daily dosage of melanin can be expected to be about 0.001 to 1000 milligrams (mg) per kilogram (kg) of body weight, with the preferred dose being 0.1 to about 30 mg/kg.
- Dosage forms contain from about 1 mg to about 500 mg of melanin per unit. In these pharmaceutical compositions, the melanin will ordinarily be present in an amount of about 0.5-95% weight based on the total weight of the composition.
- the melanins of the present invention can be used in the treatment of a variety of viral diseases including herpes viruses (such as cytomegalovirus (CMV), HSV-I, HSV-2, VZV, EBV), HPV, lentiviruses (such as HIV-1, HIV-2), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), influenza (including avian influenza viruses and human influenza viruses) and para-influenza, Human T-lymphotropic viruses (such as HTL V-1, HTL V-2), RSV, Tacaribe, Dengue, Rift Valley Fever Virus, spumavirus (human foamy virus) and feline infectious leukemia, members of the Retrovirus, Rhabdovirus, Arbovirus, Orthomyxovirus, Paramyxovirus, Filovirus, Alphavirus, Herpesvirus, Hepadnavirus, Poxvirus families, Noroviruses, Picornaviruses, as well as diseases caused by intracellular pathogen
- the melanins of the present invention can be used in the treatment of other viral diseases including amyloidogenic diseases (including Alzheimer's and multiple myeloma), Hepatitis B, and prion diseases (including kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Strassler-Scheinker Disease (GSS), and fatal familial insomnia (FFI), scrapie and bovine spongiform encephalopathy (BSE)); genital warts; common warts; plantar warts; Hepatitis C; molluscum contagiosum; variola, particularly variola major; VZV; rhinovirus; adenovirus; coronavirus; intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g.
- amyloidogenic diseases including Alzheimer's and multiple
- neoplastic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
- parasitic diseases e.g. pneumocystis camii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, and leishmaniasis.
- Additional diseases or conditions that can be treated using the compounds of the invention include actinic keratosis; eczema; eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; alopecia areata; the inhibition of Keloid formation after surgery and other types of post-surgical scars; and bacterial infections, e.g., tuberculosis, and mycobacterium avium.
- these compounds could enhance or stimulate the healing of wounds, including chronic wounds.
- the melanins of the present invention can be used in the treatment of viral diseases that affect cattle, fowl, cultured marine species, pets, and natural populations of wild animals. These diseases include herpes virus infections in cows, goats, pigs, sheep, ducks, chickens and turkeys and catfish horses, cats, and dogs, Marek's disease, avian leukosis, and viral hemorrhagic septicemia.
- the present invention includes prevention and treatment for HIV disease and associated diseases, especially those caused by enveloped viruses, in a subject such as an animal, for example a human.
- the method includes administering the melanins of the present invention, or a combination of the compound and one or more other pharmaceutical agents, to the subject in a pharmaceutically compatible carrier and in an amount effective to inhibit the development or progression of HIV disease.
- the treatment can be used prophylactically in any patient in a demographic group at significant risk for such diseases, subjects can also be selected using more specific criteria, such as a definitive diagnosis of the condition.
- the melanins of the present invention are ideally administered as soon as possible before potential or after actual exposure to HIV infection. For example, once HIV infection has been confirmed by laboratory tests, a therapeutically effective amount of the melanin is administered.
- the present invention also includes combinations of melanins with one or more agents useful in the treatment of HIV disease.
- the melanins of this invention may be administered, whether before or after exposure to the virus, in combination with effective doses of other anti-virals, immunomodulators, anti-infectives, or vaccines.
- administration refers to both concurrent and sequential administration of the active agents.
- Example of antivirals that can be used in combination with the melanins of the invention are: AL-721 (from Ethigen of Los Angeles, Calif.), recombinant human interferon beta (from Triton Biosciences of Alameda, Calif.), Acemannan (from Carrington Labs of Irving, Tex.), ganciclovir (from Syntex of Palo alto, Calif.), didehydrodeoxythymidine or d4T (from Bristol-Myers-Squibb), ELIO (from Elan Corp. of Gainesville, Ga.), dideoxycytidine or ddC (from Hoffman-LaRoche), Novapren (from Novaferon labs, Inc.
- AL-721 from Ethigen of Los Angeles, Calif.
- recombinant human interferon beta from Triton Biosciences of Alameda, Calif.
- Acemannan from Carrington Labs of Irving, Tex.
- ganciclovir from Syntex of Palo alto, Calif.
- combination therapies are of course not limited to the lists provided in these examples, but includes any composition for the treatment of HIV disease (including treatment of AIDS).
- immuno-modulators that can be used in combination with the melanins of the invention are AS-101 (Wyeth-Ayerst Labs.), bropirimine (Upjohn), gamma interferon (Genentech), GM-CSF (Genetics Institute), IL-2 (Cetus or Hoffman-LaRoche), human immune globulin (Cutter Biological), IMREG (from Imreg of New La, La.), SK&F106528, and TNF (Genentech).
- Examples of some anti-infectives with which the melanins can be used include clindamycin with primaquine (from Upjohn, for the treatment of pneumocystis pneumonia), fluconazlone (from Pfizer for the treatment of cryptococcal meningitis or candidiasis), nystatin, pentamidine, trimethaprimsulfamethoxazole, and many others.
- Banana PPO enzyme was purified from banana skins by a previously published method (C. P. Yang, et al. (2001) J. Agric. Food Chem. 49: 1446-1449). Small-scale test reactions were carried out by mixing 5 ⁇ L of enzyme solution (66 units of catechol oxidase activity) and 2.5 mg of a phenolic test substrate in 2.5 ml of 0.2 M sodium/potassium phosphate buffer, pH 7.0. A blank reaction mixture containing all of the components except the PPO enzyme was prepared for each test substrate so that enzyme-mediated pigment formation could be distinguished from the non-enzymatic oxidation of the substrate. The test mixtures and their corresponding blanks were covered with Parafilm and incubated at 23° C. for 24 hours.
- each test and blank reaction mixture was determined by measuring its ability to inhibit the infection of cultured human foreskin fibroblasts by HSV 1.
- a PPO product was considered to be soluble in aqueous solution when enzymatically formed pigment in the test reaction was present in a clear supernatant at the end of the incubation period.
- Base-soluble products were pigments that presented as cloudy or turbid suspensions or as precipitates at the end of the incubation, but were transformed into clear solutions by the dropwise addition of 0.1 N NaOH.
- Table 1 shows the results of our test of 35 potential melanogenic substrates of the PPO enzyme (E.C. 1.10.3.1) from banana ( Musa sapientum ) skin.
- the enzyme catalyzed synthesis of antiviral melanins was further tested using a purified PPO (I.U.B.: 1.14.18.1) from Agaricas bisporus (mushroom) as the catalyst. This enzyme was tested for its ability to produce antiviral melanins from 13 dihydroxy phenyl-containing substrates. For this test, 2.0 mg of substrate was added to 1 ml of 0.1 M potassium phosphate, pH 7.0 that contained 0.8 mg (22 catechol oxidase units) of mushroom PPO. Blank reaction mixes containing all ingredients except for the PPO were simultaneously evaluated.
- caffeic acid (3,4-dihydroxy cinnamic acid, Sigma Aldrich, Milwaukee, Wis., catalog No. D11, 080-9) was added to a 150 mL Erlenmeyer flask containing 60 mL of 0.1 M potassium phosphate buffer, pH 7.
- the mixture was stirred for 10 minutes at 23° C. to provide a solution with the pH of 6.73.
- the pH was adjusted to 7.0 with dilute sodium hydroxide.
- 60 mg polyphenol oxidase (PPO) 23 units per mg catechol oxidase activity, Worthington Biochemicals Corp. Lakewood N.J., Catalog No. TY was added and swirled in the flask to dissolve the enzyme.
- the flask was covered with parafilm and incubated in a block heater for 48 hours at 40° C.
- the flask was then placed in a boiling water bath for 20 minutes to inactivate and denature the PPO.
- the mixture was cooled and the pH adjusted to pH 3.5 by adding HCl.
- the flask was allowed to stand overnight under refrigeration to precipitate the enzymatically synthesized melanin product.
- This suspension was centrifuged, and the melanin pellet washed 3 times with 24 mL of 0.01 N HCl.
- the washed pellet was dissolved in 16 ml of 0.2 M sodium bicarbonate.
- This solution was dialyzed in SpectraIPor 4 cellophane dialysis tubing (10-14 kDa MWCO, Spectrum Laboratories Inc., Collinso Dominguez, Calif.) against 4 ⁇ 4 L changes of deionized water.
- the retentate was lyophilized.
- Enzymatically synthesized melanin product was recovered as a dark brown powder with a dry weight of 128 mg (85% yield).
- esculetin (6,7-dihydroxycoumarin (Sigma-Aldrich, Milwaukee, Wis., catalog No. 24,6573) was added to 60 ml of 0.1 M potassium phosphate buffer pH 7 in an Erlenmeyer flask and mixed for 10 minutes at 23° C. 60 mg of mushroom PPO was added to this saturated solution and gently swirled in the flask to dissolve the enzyme. The flask was covered with parafilm and incubated at 40° C. for 144 hours. The flask was placed in a boiling water bath, and the enzymatically synthesized melanin product, ES-EM, was isolated by acid precipitation, washing, dialysis, and lyophilization as described for ES-CAM. ES-EM was recovered as an amber colored powder with a dry weight of 116 mg (77% yield).
- ES-CAM and ES-EM prepared by the process described above were polymers that are soluble in water and in aqueous buffer solutions with pH's of 4.5 and above.
- nonenzymatically (chemically) synthesized melanins were prepared by oxidizing aqueous solutions of caffeic acid or esculetin at 40° C. and pH 9.0 for a 144 hours period during which humidified room air was continuously bubbled through the reaction mixtures.
- the final products were isolated by acid precipitation, dialysis, and lyophilization as described above.
- HPLC-GPC chromatography of ES-CAM at pH 8.6 ( FIG. 1A ) showed that the product eluted as a single peak with a number average molecular weight of 19.7 kDa.
- the ultraviolet spectrum of the peak ( FIG. 3A ) showed a nearly linear increase in absorbance as the wavelength decreased from 300 to 200 nm, a characteristic spectral feature of natural and enzymatically synthesized melanins. Superimposed on this feature were broad, subtle absorbance maxima at 230, 285, and 320 nm, the last two of which are characteristic of cinnamic acid moieties. Under the same conditions, nonenzymatically synthesized melanin prepared from caffeic acid eluted with a molecular weight of 14.7 kDa ( FIG. 1B ). The UV spectrum of this chemically synthesized melanin was similar to that of its enzyme-synthesized counterpart ( FIG. 3A ).
- FTIR spectroscopy of ES-CAM and ES-EM which was performed by McCrone Associates, Inc. (Westmont, Ill.), showed that the enzymatically synthesized melanins ES-CAM and ES-EM demonstrated strong absorption bands in 5 regions of the infrared spectrum: in the 3390 to 3450 cm ⁇ 1 region; in the 1600 to 1700 cm ⁇ 1 region; in the 1500 to 1600 cm ⁇ 1 region; in the 1360 to 1410 cm ⁇ 1 region; and in the 1220 to 1280 cm ⁇ 1 region.
- the broad band at approximately 3400 cm ⁇ 1 is attributed to OH stretching of phenolic and carboxylic acid groups.
- the bands in the 1500 to 1700 region are attributed to aromatic C ⁇ C bonds and aromatic C ⁇ C bonds conjugated with C ⁇ O and or COO— groups.
- the bands in the 1300 to 1400 region are attributed to CH2 groups of aliphatic radicals, CH neighboring to OH and COOH groups, and C ⁇ O groups of quinones.
- the bands in the 1200 to 1300 region are attributed to phenolic C—OH stretching.
- the absorbance bands for ES-CAM were observed at wavenumbers of 3397, 1616, 1508, 1389, and 1267 cm ⁇ 1 .
- the absorbance bands for ES-EM were present at wavenumbers of 3409, 1686, 1571, 1397, and 1262 cm ⁇ 1 .
- FTIR spectra are similar to those previously reported for certain natural melanins (Savia, V. M. et al., Food Chemistry 2001, 73:177-184; Turick, C. E. Applied and Environmental Microbiology 2002, 68: 2436-2444; Pigment Cell Research 2005, 18: 130-135; and Liu, Y. et al., Photochemistry and Photobiology 2005, 11:135-144) and for melanins chemically synthesized from catecholamines or quinones (Cataldo, F. Polymer International 1998, 46:263-269).
- ES-CAM and ES-EM synthesized by our enzymatic processes were analyzed by MALDI-TOF mass spectrometry by M-Scan Inc. (West Chester, Pa.). High resolution analysis in the positive ion mode using a matrix of Dithranol+AgTFA showed that both ES-CAM and ES-EM had spectra characteristic of polymers with number average molecular weights of approximately 3.6 kDa and 3.3 kDa, respectively. Both enzymatically synthesized melanins had mass spectra that indicated high degrees of polydispersity. Both melanin products contained multiple molecular species (i.e, oligomers) that differed by 24 m/z units.
- melanins were prepared from commercially available precursors, obtained from Sigma-Aldrich (St. Louis, Mo.). The melanins are designated as C1 to C18, listed in table 4.
- the chemical synthesis process was also scaled up by a factor of 10.
- the reaction mixtures of 150 mg precursor, 70 mL buffer, 300 ⁇ L of 5 mg/mL salcomine were incubated in pear flasks for 48 hours at 45° C. with a bubbling stream of air at a flow rate of 125 ml/min.
- the percent yields were similar to those reported in Table 4 and the weights of the final products were increased by approximately 10-fold.
- FIGS. 6 a , 6 b , and 6 c The results of HPLC-GPC chromatography of the chemically synthesized melanin polymers and their ultraviolet spectra are presented in FIGS. 6 a , 6 b , and 6 c .
- Eight of the chemically synthesized polymers were analyzed by FTIR ( FIGS. 7 a and 7 b ). The spectra are similar to those previously obtained for natural and enzymatically synthetic melanins.
- the differences in the FTIR spectra of ES-CAM and C11 and between the FTIR spectra of ES-EM and C10 illustrate structural differences in polymers made from the same precursors by the two different processes—one enzymatic and one chemical.
- ES-CAM ES-EM Precursor: Caffeic Acid Esculetin Virus Strain 2 HSV-IF 1.00 2.00 Clin 61665 1.00 2.00 15985 (AR) 1.00 2.00 Clin 10301(AR) 1.00 1.00 HSV-2G 0.25 1.00 Clin 23235 0.50 2.00 Clin 27071 0.25 1.00 Clin 16064 (AR) 0.50 1.00 CMV AD169 0.25 1.00 Clin D16 (GR) 0.25 0.50 Clin OBR (GR) 0.12 0.50 HIV BAL strain 0.21 0.036 1
- the anti-HSV assay was an in situ ELISA performed with minor modifications (Thompson and Dragar, Phytotherapy Research 18: 551-555, 2004).
- the anti-CMV assay was a plaque reduction assay and was performed with minor modification (Sullivan, V., et.al., Antimicrobial Agents and Chemotherapy 37: 19-25, 1993).
- 2 Clin virus strain is a primary isolate obtained from an infected human; AR; acyclovir resistant; GR: ganciclovir resistant.
- the anti-HIV results were determined by the Viral Quality Assurance Laboratory at Rush University directed by James Bremer, Ph.D.
- the VQA laboratory is responsible for establishing the quality control testing for all AIDS Clinical Trial Group (ATCG) laboratories in the U.S.
- the results with ES-CAM and ES-EM using a laboratory strain of HIV tested in the VQA laboratory were 0.21 ug/mL and 0.036 ug/mL respectively.
- the enzymatically synthesized ES-CAM and ES-EM prepared according to this invention will prevent many different viral infections including HSV and HIV by acting as inhibitors of virus binding and/or virus fusion.
- Melanins that were nonenzymatically synthesized from caffeic acid and esculetin precursors by spontaneous polymerization at a basic pH typically had maximum anti-HSV 1 potencies (ED50) of ⁇ 4 ⁇ g/mL.
- ED50 anti-HSV 1 potencies
- BAL HIV-1 strain was used in the HIV assay. The cells were exposed to the compounds for 1 hour prior to infection with the BAL HIV-1 strain (200 TCID50/200,000 cells). The cells (200,000 cells per well) were infected overnight and the next day 100 ⁇ L of supernatant was removed and 100 ⁇ L of fresh compound media was added to the appropriate wells. At day 4, 125 ⁇ L of supernatant was removed and 150 ⁇ L of compound media was added. At day 7, the supernatant was diluted 1:1560 and tested using Perkin-Elmer's HIV-1 p24 kit.
- the enzymatically synthesized melanins ES-CAM and ES-EM and 8 of the chemically synthesize melanins were submitted to the National Institute of Allergy and Infectious Diseases (NIAID) Antimicrobial Acquisition and Coordinating Facility (Project Officer Dr. Chris Tseng) to be tested for in vitro activity against 7 Types of herpesviruses; 7 respiratory viruses; 2 orthopoxviruses, and a Biodefense panel of 10 viruses as well as for in vivo activity testing in animal models for herpesviruses, respiratory viruses, and scrapie.
- NIAID National Institute of Allergy and Infectious Diseases
- the details of the assay protocols used for testing and the investigators that carried out the testing are described on the NIAID website. The results that have been reported to date are presented in Tables 5-14.
- the synthetic melanins demonstrate activity toward a number of respiratory viruses (tables 7-11). Especially significant are the high potencies of 4 of our compounds toward Influenzas A (including H5N1) and B. Since the portals of entry of the respiratory viruses and many other clinically important enveloped viruses are the epithelial surfaces of the oral cavity, the nasopharynx, the respiratory tract (and possibly the GI Tract) and the conjunctiva, antiviral prophylaxis or treatment could be delivered by non parenteral application, such as drops, oral solutions, sprays or nebulized droplets.
- ESEM, C2, C9 and C12 have high potencies against VZV with EC50's in the range of 0.03 to 3.9 ⁇ g/mL.
- AVC Acyclovir
- Cytotoxicity study showed all of these four melanins have CC50's larger than 100 ⁇ g/mL. None of the compounds tested had significant in vitro activity against EBV.
- VZV(Varicella Zoster Virus) ACV Cmpd EC50 EC90 CC50 SI EC50 ESCAM nt nt nt nt 0.06 ESEM ⁇ 0.0300 ⁇ 0.0300 >100 >3333 0.06 C1 36 49.3 >100 >2.8 0.17 C2 3.9 31.7 >100 >26 0.17 C4 10 43.4 >100 >10 0.17 C9 3.7 >100 >100 >27 0.17 C11 64.8 95.7 >100 >1.5 0.06 C12 ⁇ 0.0300 ⁇ 0.0300 >100 >3333 0.06 C17 nt nt nt 0.06 nt: Compound not tested.
- EBV Epstein-Barr Virus
- ACV EC50 ESCAM 98.3 >100 >100 >1 2.7 ESEM >100 >100 >100 0 2.7 C1 >100 >100 >100 0 0.7 C2 >100 >100 >100 >100 0 0.7 C4 >100 >100 >100 >100 0 0.7 C9 >20 >20 >20 0 0.7 C11 >20 >20 >20 0 0.7 C12 >100 >100 >100 0 0.7 C15 >100 >100 >100 0 0.7 C17 >100 >100 >100 0 0.7
- lysozyme hen egg white, 20 mg/mL
- Solutions of lysozyme were incubated in 20 mM glycine-HCl buffer at 58° C. for 8 days in the presence of one of the melanins.
- the incubation mixtures were sampled repeatedly and the kinetics of lysozyme fibrillation were evaluated by Thioflavin T (Tht) fluorescence, native PAGE, and fluorescence and dark field microscopy.
- Thioflavin T (Tht) fluorescence, native PAGE, and fluorescence and dark field microscopy Compounds C11, ES-EM, and C12 ( FIG. 8 ) inhibited the development of THT fluorescence to levels that were 16%, 42%, and 61%, respectively, of untreated control mixtures.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- The present application claims priority to U.S. Provisional Patent Application No. 61/008,948, filed Dec. 21, 2007, the entirety of which is hereby incorporated by reference.
- 1. Technical Field
- The present invention provides the chemical and enzyme-catalyzed synthesis of melanins. The synthesized melanins inhibit the binding of viruses to animal cells, prevent a virus from infecting the cells of its host, and prevent the spread of viral infections from person-to-person.
- 2. Background Information
- Melanin is a general term for a group of high molecular weight black and brown pigments that arise from the oxidation and polymerization of polyphenols and aromatic amino acids (Prota, G., Melanins and Melanogenesis. 1992, San Diego: Academic Press, Inc. 1-290; Riley, P. A., Int. J. Biochem. Cell Biol. (1997) 29(11):1235-1239). Melanins are normal constituents of animal and plant tissues and are also present in many microorganisms. Melanins contribute to the coloration of the skin and hair of animals, the seeds, berries, flowers, and leaves of plants and to subcellular structures in certain bacteria and fungi. Despite many years of careful study, the precise chemical structures of natural melanins are virtually unknown. Structural elucidation has been hampered because of four main factors: the low molecular weight phenolic precursors of melanins are highly diverse; the oligomeric polyphenol units of natural melanins contain substituents that exist in several different oxidation states and as multiple structural isomers; melanins are typically isolated as heterogeneous mixtures; and melanins are resistant to analytical approaches based on chemical degradation. The potential for variability in melanin structure is so great that it may well be that no two melanin pigments are absolutely identical.
- Melanins are typically identified by their unique physicochemical properties including their solubility characteristics, their tendency to aggregate in the presence of metal ions, their characteristic adsorption spectra in the UV and infrared regions, their ability to act as semi-conductors, their decolorization by strong oxidizing agents, their antioxidant and radioprotective properties, and their resistance to hydrolysis under strongly acidic and strongly basic conditions. Natural and enzymatically synthesized melanins exhibit strong absorption throughout the UV and visible regions. Published spectra are characterized by a monotonic increase in the absorbance with decreasing wavelengths with a barely detectable shoulder between 290 and 320 nm. The infrared spectra of melanins show absorption bands expected for an aromatic or a heteroaromatic system of OH, NH, and conjugated carbonyl groups. Recent analyses of a natural melanin from Sepia officinalis using a combination of scanning electron microscopy, atomic force microscopy, x-ray scattering, and mass spectrometry are consistent with the notion that natural melanins are comprised of small oligomeric units that aggregate to form stable filaments, particles (5-200 nm in diameter) and aggregates of the particles (Clancy, C. M. et al., Biochemistry (2001) 40 (44):13353-13360). These data suggest that the molecular constituents of melanin oligomers are made up of 4 to 8 monomer units. The oligomers have masses in the range of 500 to 1500 amu. Even after extensive investigations of this well-known natural melanin using the most sophisticated analytical approaches available, neither the precise structures of the melanin polymer nor that of the oligomeric constituents have been ascertained. Regardless of the source, it is unlikely that natural melanins are derived from unique well-defined building blocks.
- The bulk of the scientific literature on melanin structure and function pertains to the mammalian melanins. Considerably less is known about the plant-derived melanins even though they are an abundant constituent of the biomass. The biosynthesis of plant melanins is catalyzed by a family of Type III polyketide synthetases (e.g., chalcone synthetase) which catalyze the first committed step in the synthesis of a large number of biologically important flavonoids and phytoalexins. The PKS III enzymes utilize a starter CoA-ester (e.g., p-coumaroyl-CoA) from the phenylpropanoid pathway and catalyze three sequential condensation reactions with an extender CoA-ester (e.g., malonylCoA). This is followed by a ring closure, and an aromatization to form chalcones (e.g., naringenin). Many different aromatic phenolics can be made by this mechanism depending on which polyketide synthetase is present and which of the many possible starter and extender CoA-esters are available for incorporation. The aromatic phenols and polyphenols that are the products of the polyketide pathway in a particular plant are oxidized to quinones by the enzyme polyphenol oxidase. The quinones are then joined together by free radical polymerization reactions to form oligomers that contain a mixture of quinone, hydroquinone, and semi-quinone functional groups. The oligomers associate to form stable, non-covalent complexes that take the form of particles, aggregates of particles, and fibers and exhibit the distinctive physical and chemical characteristics of the natural melanins.
- Traditionally, melanins have been isolated from plants as heterologous, crude or purified preparations. Banister et al. (U.S. Pat. No. 6,303,106) describes the enzymatic production of melanins from phenolic compounds and an enzyme selected from tyrosinase, laccase and peroxidase. The produced melanins are used in the production of cosmetics.
- The published literature concerning the use of plant-derived melanins as therapeutic agents is minimal. However, there have been a number of publications describing the isolation and characterization of melanins from fermented black tea (Sava, V. M. et al., Food Chemistry (2001) 73: 177-184) and from grapes (Novikov, D. A. et al., Radiats. Biol. Radioecol. (2001) 41(6):664-670; Avramidis, N., et al., Arzneimittelforschung. (1998) 48(7): 764-771). These plant-derived melanins have been shown to possess a number of interesting pharmacological properties including immunomodulatory activity (Avramidis, 1998; Sava, V. M. et al., Food Research International (2001) 34: 337-343), photoprotective activity (Novikov, 2001), metal binding properties that make them useful as image enhancers in MRI (Hung, Y. C. et al., J. Ethnopharmacol. (2002) 79(1): 75-79), and the ability to protect animals from oxidant-induced tissue damage (Hung, Y. C. et al., Life Sci. (2003) 72(9): 1061-1071). Montefiori (U.S. Pat. No. 5,057,325) describes inhibition of human immunodeficiency virus (HIV) by enzymatically synthesized melanins, preferably melanins containing subunits of L-Dopa.
- Synthetic melanins have been shown to have activity against HIV infections in in vitro cell culture models (Novikov, 2001; Garger, U.S. Pat. No. 6,440,691). The intrathecal administration of synthetic and natural melanins has been proposed as a treatment for certain neurodegenerative diseases, however evidence for their effectiveness has yet to be presented (Berliner, U.S. Pat. No. 5,817,631).
- Crude and purified preparations of plant-derived melanins prevent viral infections by interfering with early steps in the infectious process namely the attachment of a virus to the epithelial cell membranes of a potential host and/or the fusion of the viral membrane with that of the host cell (Holmes, E. W. and Thompson, K. D., FASEB 1.19, (2005) Abstract No. 323.5, 2005). Host cells are protected from infection after only a brief period of melanin treatment and the protection afforded by the treatment persists for hours. Plant melanins are nontoxic to animal cells in vitro and cause no adverse effects following intravaginal administration in mice. Such properties make them ideal for the prevention of viral infections for which the portal of entry is the epithelium of the host.
- Melanins have been chemically synthesized from hydroxyphenyl-containing precursors, mostly focused on catecholamines and catecholamine derivatives (e.g. DOPA, Dopamine, etc). Quinones are generated at basic pH spontaneously, followed by polymerization. However, the resulting polymers are often found to be poorly soluble in biocompatible solvents, and hence, are not likely to be useful as pharmaceuticals. Another disadvantage of many of the synthetic polymers of hydroxyphenyl compounds is that data documenting the scopes and potencies of their antimicrobial activities is either limited or unavailable.
- It would be desirable to synthetically produce melanins in high yields under reproducible conditions. Further, it would be desirable to produce novel melanins, especially water-soluble melanins, with antiviral activity.
- The present invention provides a method for producing a melanin comprising the step of: (a) contacting an oxidase and a phenolic substrate containing at least two hydroxyl groups for a time sufficient to produce a melanin. The method can optionally further comprise any of the following steps: (b) inactivating the oxidase, (c) precipitating the melanin, and/or (d) purifying the melanin.
- The present invention further provides a melanin produced by the step of (a) contacting (1) an oxidase and (2) at least one phenolic substrate with at least two hydroxyl groups for a time sufficient to produce a melanin. The method of the present invention can be used to produce novel homologous (single PPO substrate) and heterologous (two or more PPO substrates) melanins, including enzymatically synthesized melanins comprising bicyclic dihydroxyphenolic monomers.
- The present disclosure also provides a method for the chemical synthesis of a melanin. The method comprises the step of: (a) contacting a phenolic substrate and a catalyst for a time sufficient to produce a melanin. The method can optionally further comprise the step of: (b) purifying the melanin. The substrate contains two or more aromatic hydroxyl-groups.
- The present invention includes novel enzymatically and chemically synthesized melanins, including those prepared from cinnamic acid and those prepared from coumarin. The melanins of the present invention are typically water soluble.
- The present invention further provides antiviral compositions, especially compositions suitable for intravaginal, intrarectal, or topical use.
- The enzymatically and chemically synthesized melanins of the present invention can be used to prevent infections, especially those that are caused by enveloped viruses, and those which are sexually transmitted.
-
FIG. 1 is a HPLC-GPC chromatogram of enzymatically synthesized caffeic acid melanin (“ES-CAM”) and non-enzymatically synthesized caffeic acid melanin. ES-CAM prepared by the enzymatic process described in this disclosure (A) and caffeic acid melanin prepared by a nonenzymatic synthesis procedure (B) were analyzed by HPLC on a column of BioSep SEC-S2000. The mobile phase, 0.05 M sodium borate, pH 8.6, was pumped at a flow rate of 0.75 mL/min. Compounds in the effluent were detected by their absorbances at 220 nm using a diode array detector. The column was calibrated with polymer standards of known molecular weights to enable the estimation of molecular weight based on retention time. -
FIG. 2 is a HPLC-GPC chromatogram of enzymatically synthesized esculetin melanin (“ES-EM”) and nonenzymatically-synthesized esculetin melanin ES-EM prepared by the process described in this disclosure (A) and nonenzymatically synthesized esculetin melanin (B) were analyzed as described in the legend toFIG. 1 . -
FIG. 3 is the absorbance spectra of ES-CAM and ES-EM and their nonenzymatically synthesized analogues. The UV spectra at the retention times corresponding to the peaks labeled inFIGS. 1 and 2 were recorded with a diode array detector. -
FIG. 4 is the FTIR spectra of ES-CAM and ES-EM. ES-CAM or ES-EM were lyophilized and ground into a powder. A sample of the dry solid was pressed on to the surface of polished potassium bromide salt plate and analyzed using a Thermo-Nicolet Nexus FTIR bench and a Continuum microscope with an MCT detector. The spectra were collected at 8 cm−1 resolution. -
FIG. 5 is a MALDI-TOF mass spectrum of ES-EM. ES-EM was diluted with a matrix consisting of 10 mg/mL, DHBA in ethanol/water ITF A, 50/50/0.1 (v/v/v), spotted on a gold target, and analyzed with a Ciphergen PBS II mass spectrometer. The spectrometer was operated in the positive ion mode at a laser intensity of 240 and a sensitivity of 6. -
FIG. 6 a is the HPLC-GPC chromatograms and UV spectra of chemically synthesized melanins C1-C6. The compounds are listed in table 4. -
FIG. 6 b is the HPLC-GPC chromatograms and UV spectra of chemically synthesized melanins C7-C12. The compounds are listed in table 4. -
FIG. 6 c is the HPLC-GPC chromatograms and UV spectra of chemically synthesized melanins C13-C18. The compounds are listed in table 4. -
FIGS. 7 a is the FTIR spectra of chemically synthesized melanins C1, C2, C4, and C9. -
FIGS. 7 b are the FTIR spectra of chemically synthesized melanins C10, C11, C12, and C17. -
FIG. 8 illustrates the effect of the synthetic melanins ES-EM, C11, and C12 on Lysozyme Fibrillation in vitro. - Enzymatic Methods
- The present invention provides a method for producing a melanin comprising the step of: (a) contacting a polyphenol oxidase (PPO) and a pyrocatechol substrate for a time sufficient to produce a melanin. The method can optionally further comprise any of the following steps: (b) inactivating the oxidase, (c) precipitating the melanin, and/or (d) purifying the melanin.
- Typically, the PPO and pyrocatechol substrate are contacted for at least 6 hours, preferably at least 12 hours, more preferably at least 24 hours. The enzymatic reaction is typically conducted in aqueous media, at a neutral pH, and at least at room temperature.
- The reaction can be terminated by inactivating the PPO either chemically, by altering the pH of the reaction (for example, by adding base or acid), or physically (by heating or cooling the reaction).
- Melanin can be purified from the reaction mixture by precipitation (as described below in the examples), centrifugation, chromatography and other well known methods.
- Polyphenol Oxidase
- Any PPO can be used in accordance with the present invention. PPOs can be isolated from mammalian, plant and fungal sources. Exemplary PPOs include banana and mushroom PPO enzyme and tyrosinases from various sources. Preferably, mushroom PPO enzyme is used. Any activity of enzyme can be used.
- PPO Substrates
- The substrates of the present invention are pyrocatechol substrates. In some cases, tri-hydroxyl benzene substrates can be used.
- The pyrocatechol substrates of the present invention typically have one of the following cores:
- These cores can have one or more substituents including hydroxyl, amino, thiol, carbonyl, unsubstituted or substituted alkyl, unsubstituted or substituted-8-carbocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclyl, and unsubstituted or substituted heteroaryl. In formula (III), one or none of the dashed lines can be a double bond. Other cores can also be used.
- When more than one substrate is used, at least one substrate must be a pyrocatechol substrate; however the other substrate(s) may be a phenolic substrate or any other molecule containing an electron-rich center or functional group, for example, a conjugated double bond, an amino group, or a sulfhydryl group. By combining mixtures of substrates, novel melanins can be obtained. In one embodiment, the pyrocatechol substrate is a bicyclic compound such as esculetin, dapthnetin, catechin, baicalein or alizarin. In another embodiment, the pyrocatechol substrate is a monocyclic compound.
- Exemplary pyrocatechol substrates useful in the present invention are shown below in Table 1. Exemplary phenolic substrates include dopamine, L-DOPA, catechin hydrate, pyrocatechol, protocatechuric acid, serotonin, DOPAC, deoxyepinephrine, isoproterenol, norepinephrine, epinephrine bitartrate, baicalein, 2,3-dihydroxybenzoic acid, esculetin, 2,3,4-trihydroxybenzoic acid, quercetin, gallic acid, 2,3,4-trihydroxybenzaldehyde, alizarin, 2,3-dihydroxynapthalene, pyrogallol, caffeic acid, nordihydroguaiaretic acid, daphnetin, phenol red, and 4-methyl daphnetin.
- In one embodiment, the phenolic substrate is selected from the group consisting of dopamine, L-DOPA, caffeic acid, protocatechuric acid, DOPAC, deoxyepinephrine, gallic acid or pyrogallol.
- In one embodiment, an initial amount of PPO substrate can be coupled to a solid phase. Thereafter the polymerization reaction can be conducted in solution by exposing the solid phase to enzyme and further PPO substrate. In this way, the formed melanin can be easily manipulated and isolated.
- Novel Enzymatically Synthesized Melanins
- Enzymatically synthesized melanins prepared by this invention are generally found to be soluble in aqueous solutions at pH's that are within the physiological range for humans and other animal species.
- Enzymatically synthesized melanins prepared by this invention typically are composed of 50 to 200 substrate monomers. These melanins are typically aggregates of oligomers with different degrees of polymerization.
- In one preferred embodiment, the enzymatically synthesized melanin is prepared from the phenolic substrate caffeic acid. Such melanins are water-soluble, and are composed of oligomers with molecular weights in the range of approximately 1.2 to 5.4 kDa which, in turn, aggregate in aqueous solution to form complexes with a number average molecular weight of approximately 19.7 kDa.
- In another preferred embodiment, the enzymatically synthesized melanin is prepared from the phenolic substrate esculetin. Such melanins are water-soluble and are composed of oligomers with molecular weights in the range of approximately 1.0 to 5.0 kDa which, in turn, aggregate in aqueous solution to form complexes with a number average molecular weight of approximately 15.4 kDa.
- Enzymatically synthesized melanins prepared according to this invention are water soluble polymers of sufficient molecular weight to be nondialyzable through standard dialysis membranes with molecular weight cutoffs in the range of 10 to 13 kDa. The enzymatically synthesized melanins precipitate at pH's of less than 4.5. These enzymatically synthesized melanins typically have ultraviolet absorbance spectra that are characterized by steep increases in absorbance as the excitation wavelength decreases from 300 to 200 nm. Such melanins typically have FTIR spectra that demonstrate strong absorption bands in at least some of the following regions: at approximately 3400 cm−1; in the 1600 to 1700 cm−1 range; in the 1500 to 1600 cm−1 range; in the 1360 to 1410 cm−1; and in the 1220 to 1280 cm−1 range. Enzymatically synthesized melanins prepared according to this invention typically have positive ion MALDI TOF mass spectra that show partially resolved distributions of singly-charged pseudo-molecular ions between approximately 1000 and 5400 m/z units. These results show that enzymatically synthesized melanins are heteropolymers composed of lower molecular weight oligomers of different degrees of polymerization. The mass spectra further suggest that the higher molecular weight oligomers contain multiple intra-chain ring closures that produce extended polynuclear (i.e. graphite-like) structures.
- Chemical Methods
- The present disclosure also provides a method for the chemical synthesis of a melanin. The method comprises the step of: (a) contacting a phenolic substrate and a catalyst for a time sufficient to produce a melanin. The method can optionally further comprise the step of: (b) purifying the melanin. The substrate contains two or more aromatic hydroxyl-groups.
- The reaction is typically conducted in aqueous media, at a basic pH and at an elevated temperature. The resulting melanin can be purified from the reaction mixture by dialysis, chromatography and other well know methods.
- The examples of the catalyst include iron, cobalt and nickel complexes. The preferred example is N,N′-bis(salicylidene)ethylenediaminocobalt (II) (salcomine).
- Exemplary substrates include pyrogallol, quercetin dihydrate, daphnetin, 2,3-dihydroxynapthalene, 3,4 dihydroxybenzoic acid (protocatechuric acid), 6,7-dihydroxy-4-coumarinyl acetic acid, baicalein, gallic acid, 3,4-dihydroxyphenylacetic acid, esculetin, caffeic acid, catechin, nordihydroquaiuretic acid, baicalein hydrate, 2,3,4-trihydroxybenzoic acid, epinephrine (bitartrate), epinine (2-deoxy norepinephrine), and 2,3,4-trihydroxybenzaldehyde.
- In the disclosed embodiments, 18 homopolymers were synthesized using the 18 different precursors, listed in Table 4. The chemically synthesized polymers are highly water-soluble compared to catecholamine-derived synthetic melanins and natural melanins derived from Sepia or human hair. The products are stable as dry powders (possibly indefinitely). The synthetic polymers are likely to be structurally unique polymers that have not been previously described, and may also serve as lead compounds for the development of derivatives that may have additional unique and useful activities or applications. Synthetic melanins can be used as components of multi-agent prophylaxis or treatment regimens in which multiple mechanisms of microbial infection are simultaneously targeted. The melanins made using this process are active against many different viruses including HIV,
HSV 1, andHSV 2, CMV, VZV, Influenzas A and B, SARS, Vaccinia, Cowpox, RSV, Tacaribe, Dengue, and Rift Valley Fever, and have low toxicities toward animal cells. They may be used as for the prevention of diseases such as herpes and AIDS in humans as well as diseases caused by a number of different enveloped viruses that infect insects, crustaceans, fish, cattle, poultry and other animal species. - This method represents the first demonstration of the generalizability of a rational chemical synthetic process for the production of synthetic melanins from a wide variety of dihydroxyphenol-containing compounds. The combination of buffer-regulated, moderately basic pH and a cobalt complex (such as salcomine) enables the formation of reactive para-quinones, and molecular oxygen into a process for the synthesis. The synthetic approach may be used to prepare homo- or hetero-polymers from many different hydroxyphenol-containing substrates, and also makes it possible to incorporate mono-hydroxylphenols into synthetic homo- or hetero-polymers analogs. The process is scalable and provides reasonable yields of products.
- Compositions
- Melanins of the present invention can be formulated into compositions by the addition of a pharmaceutically acceptable carrier. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
- The pharmaceutically acceptable carriers described herein, for example, vehicles, adjuvants, excipients, or diluents, are well-known to those who are skilled in the art. Typically, the pharmaceutically acceptable carrier is chemically inert to the active compounds and has no detrimental side effects or toxicity under the conditions of use. The pharmaceutically acceptable carriers can include polymers and polymer matrices.
- The compounds of the invention may be administered topically to the skin or mucosa, either dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated (for example, as described in Finnin and Morgan, J. Pharm. Sci., 88(10): 955-958 (October 1999)). Other means of topical administration include delivery by iontophoresis, electroporation, phonophoresis, sonophoresis and microneedle or needle-free injection.
- The melanin can be administered orally in solid dosage forms, such as lozenges, capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, mouthwashes and suspensions. It can also be administered parenterally, in sterile liquid dosage forms. The melanin can also be administered intranasally (nose drops) or by inhalation of a drug powder mist. Other dosage forms are potentially possible such as, administration transdermally, via patch mechanism or ointment. The melanin can be administered employing a sustained or delayed release delivery system or an immediate release delivery system.
- Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the melanin, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, propylene glycol, glycerin, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch. Tablet forms can include one or more of the following: lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Lozenge forms can comprise the melanin in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the melanin in an inert base, such as gelatin and glycerin, or sucrose and acadia, emulsions, and gels containing, in addition to the melanin, such carriers as are known in the art.
- The compounds of the present invention, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, and nitrogen. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, such as poly(ethyleneglycol) 400, glycerol ketals, such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
- Oils which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for use in parenteral formulations include fatty acid alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyldialkylammonium halides, and alkylpyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-aminopropionates, and 2-alkylimidazoline quaternary ammonium salts, and (e) mixtures thereof.
- The parenteral formulations typically contain from about 0.5% to about 25% by weight of the melanin in solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5% to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
- Pharmaceutically acceptable excipients are also well-known to those who are skilled in the art. The choice of excipient will be determined in part by the particular compound, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical composition of the present invention. The following methods and excipients are merely exemplary and are in no way limiting. The pharmaceutically acceptable excipients preferably do not interfere with the action of the melanins and do not cause adverse side-effects. Suitable carriers and excipients include solvents such as water, alcohol, and propylene glycol, solid absorbants and diluents, surface active agents, suspending agent, tableting binders, lubricants, flavors, and coloring agents.
- The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets. The requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, J. B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, Eds., 238-250 (1982) and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., 622-630 (1986).
- The melanins of the present invention can be formulated as:
- 1. Coatings on medical grade substrates, for example, dressings, packings, meshes, films, filtering surfaces, filters, infusers, fibers such as dental floss or sutures, containers or vials, from materials composed of, for example, polyethylene, high density polyethylene, polyvinylchloride, latex, silicone, cotton, rayon, polyester, nylon, cellulose, acetate, carboxymethylcellulose, alginate, chitin, chitosan and hydro fibres;
- 2. Powders or as coatings on biocompatible substrates in powder form, preferably on hydrocolloids, bioabsorbable and/or hygroscopic substrates such as: synthetic bioabsorbable polymers (for example polyesters/polylactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., polyanhydrides, polyesteramides, polyorthooesters, polyphosphazenes, and copolymers of these and related polymers or monomers) or naturally derived polymers (for example, proteins such as albumin, fibrin, collagen, elastin; polysaccharides such as chitosan, alginates, hyaluronic acid; acellular matrix materials such as small intestinal submucosa; and biosynthetic polyesters such as 3-hydroxybutyrate polymers);
- 3. Occlusions or hydrated dressings, in which the dressing is impregnated with a powder or solution, or is used with a topical formulation, with such dressings for example as hydrocolloids, hydrogels, polyethylene, polyurethane, polvinylidine, siloxane or silicone dressings;
- 4. Gels, formulated with powders or solutions of the melanins with such materials as hydrocolloid powders such as carboxymethylcellulose, alginate, chitin, chitosan and hydro fibres, together with such ingredients as preservatives, pectin and viscosity enhancers;
- 5. Creams, lotions, pastes, foams and ointments formulated with powders or solutions of the melanins, for example as emulsions or with drying emollients;
- 6. Liquids, formulated as solutions, dispersions, or suspensions, by dissolving coatings or powders of the melanins, for example as topical solutions, aerosols, mists, sprays, drops, infusions and instillation solutions for body cavities and tubes such as the bladder, prostate, perineal, pleural, intestinal and alimentary canal;
- 7. Formulations suitable for administration to the nasal membranes, the oral cavity or to the gastrointestinal tract, formulated with powders or liquids of the melanins in such forms as lozenges, toothpastes, gels, powders, coated dental implants, dental floss or tape, chewing gum, wafers, mouth washes or rinses, drops, sprays, elixirs, syrups, tablets, or capsules;
- 8. Formulations suitable for vaginal or rectal administration formulated with powders or liquids of the melanin formulated in or coated on such forms as suppositories, dressings, packings, condoms, tampons, diaphragms, creams, gels, ointments, pastes, foams, sprays, and solutions for retention enemas or instillations. Transvaginal drug delivery is a well known means of administering drugs to a female (Woolfson, A. D., Malcolm, R. K. and Gallagher, R. (2000) Critical Reviews in Therapeutic Drug Carrier Systems, 17:509 555). Known transvaginal drug delivery systems include mucoadhesive gels and hydrogels (such as weakly crosslinked polymers which are able to swell in contact with water and spread onto the surface of mucus); vaginal tablets (formulated with mucoadhesive polymers in order to increase intravaginal residence time); vaginal pessaries and suppositories (such as natural gums, fatty acids, alum and rock salts); microspheres for the delivery of peptide and protein drugs; and intravaginal rings (torus-shaped polymeric devices designed to release one or more incorporated substances in a controlled fashion). Additionally, formulations suitable for rectal administration may be presented as suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.
- Melanins of the present invention can be used for either prevent or treatment of viral diseases.
- “HIV disease” refers to a well recognized constellation of signs and symptoms (including the development of opportunistic infections) in persons who are infected by an HIV virus, as determined by antibody or western blot studies. Laboratory findings associated with this disease are a progressive decline in T-helper cells.
- The dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the animal over a reasonable time frame.
- One skilled in the art will recognize that dosage will depend upon a variety of factors including a condition of the animal, the body weight of the animal, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, etc. The size of the dose also will be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of the compound and the desired physiological effect.
- A daily dosage of melanin can be expected to be about 0.001 to 1000 milligrams (mg) per kilogram (kg) of body weight, with the preferred dose being 0.1 to about 30 mg/kg. Dosage forms (compositions suitable for administration) contain from about 1 mg to about 500 mg of melanin per unit. In these pharmaceutical compositions, the melanin will ordinarily be present in an amount of about 0.5-95% weight based on the total weight of the composition.
- The melanins of the present invention can be used in the treatment of a variety of viral diseases including herpes viruses (such as cytomegalovirus (CMV), HSV-I, HSV-2, VZV, EBV), HPV, lentiviruses (such as HIV-1, HIV-2), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), influenza (including avian influenza viruses and human influenza viruses) and para-influenza, Human T-lymphotropic viruses (such as HTL V-1, HTL V-2), RSV, Tacaribe, Dengue, Rift Valley Fever Virus, spumavirus (human foamy virus) and feline infectious leukemia, members of the Retrovirus, Rhabdovirus, Arbovirus, Orthomyxovirus, Paramyxovirus, Filovirus, Alphavirus, Herpesvirus, Hepadnavirus, Poxvirus families, Noroviruses, Picornaviruses, as well as diseases caused by intracellular pathogens such as Listeria, Mycobacteria, Brucella, Salmonella, Rickettsia, Trophyrema, Cryptococcus, Cryptosporidium, Microsporidium, and bacterial toxins such as that of C. difficile.
- The melanins of the present invention can be used in the treatment of other viral diseases including amyloidogenic diseases (including Alzheimer's and multiple myeloma), Hepatitis B, and prion diseases (including kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Strassler-Scheinker Disease (GSS), and fatal familial insomnia (FFI), scrapie and bovine spongiform encephalopathy (BSE)); genital warts; common warts; plantar warts; Hepatitis C; molluscum contagiosum; variola, particularly variola major; VZV; rhinovirus; adenovirus; coronavirus; intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g. candida, aspergillus, and cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; and parasitic diseases, e.g. pneumocystis camii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, and leishmaniasis. Additional diseases or conditions that can be treated using the compounds of the invention include actinic keratosis; eczema; eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; alopecia areata; the inhibition of Keloid formation after surgery and other types of post-surgical scars; and bacterial infections, e.g., tuberculosis, and mycobacterium avium. In addition, these compounds could enhance or stimulate the healing of wounds, including chronic wounds.
- The melanins of the present invention can be used in the treatment of viral diseases that affect cattle, fowl, cultured marine species, pets, and natural populations of wild animals. These diseases include herpes virus infections in cows, goats, pigs, sheep, ducks, chickens and turkeys and catfish horses, cats, and dogs, Marek's disease, avian leukosis, and viral hemorrhagic septicemia.
- The present invention includes prevention and treatment for HIV disease and associated diseases, especially those caused by enveloped viruses, in a subject such as an animal, for example a human. The method includes administering the melanins of the present invention, or a combination of the compound and one or more other pharmaceutical agents, to the subject in a pharmaceutically compatible carrier and in an amount effective to inhibit the development or progression of HIV disease. Although the treatment can be used prophylactically in any patient in a demographic group at significant risk for such diseases, subjects can also be selected using more specific criteria, such as a definitive diagnosis of the condition.
- The melanins of the present invention are ideally administered as soon as possible before potential or after actual exposure to HIV infection. For example, once HIV infection has been confirmed by laboratory tests, a therapeutically effective amount of the melanin is administered.
- The present invention also includes combinations of melanins with one or more agents useful in the treatment of HIV disease. For example, the melanins of this invention may be administered, whether before or after exposure to the virus, in combination with effective doses of other anti-virals, immunomodulators, anti-infectives, or vaccines. The term “administration” refers to both concurrent and sequential administration of the active agents.
- Example of antivirals that can be used in combination with the melanins of the invention are: AL-721 (from Ethigen of Los Angeles, Calif.), recombinant human interferon beta (from Triton Biosciences of Alameda, Calif.), Acemannan (from Carrington Labs of Irving, Tex.), ganciclovir (from Syntex of Palo alto, Calif.), didehydrodeoxythymidine or d4T (from Bristol-Myers-Squibb), ELIO (from Elan Corp. of Gainesville, Ga.), dideoxycytidine or ddC (from Hoffman-LaRoche), Novapren (from Novaferon labs, Inc. of Akron, Ohio), zidovudine or AZT (from Burroughs Wellcome), ribaririn (from Viratek of Costa Mesa, Calif.), alpha interferon and acyclovir (from Burroughs Wellcome), Indinavir (from Merck & Co.), 3TC (from Glaxo Wellcome), Ritonavir (from Abbott), Saquinavir (from Hoffmann-LaRoche), and others.
- The combination therapies are of course not limited to the lists provided in these examples, but includes any composition for the treatment of HIV disease (including treatment of AIDS).
- Examples of immuno-modulators that can be used in combination with the melanins of the invention are AS-101 (Wyeth-Ayerst Labs.), bropirimine (Upjohn), gamma interferon (Genentech), GM-CSF (Genetics Institute), IL-2 (Cetus or Hoffman-LaRoche), human immune globulin (Cutter Biological), IMREG (from Imreg of New Orleans, La.), SK&F106528, and TNF (Genentech).
- Examples of some anti-infectives with which the melanins can be used include clindamycin with primaquine (from Upjohn, for the treatment of pneumocystis pneumonia), fluconazlone (from Pfizer for the treatment of cryptococcal meningitis or candidiasis), nystatin, pentamidine, trimethaprimsulfamethoxazole, and many others.
- Banana PPO enzyme was purified from banana skins by a previously published method (C. P. Yang, et al. (2001) J. Agric. Food Chem. 49: 1446-1449). Small-scale test reactions were carried out by mixing 5 μL of enzyme solution (66 units of catechol oxidase activity) and 2.5 mg of a phenolic test substrate in 2.5 ml of 0.2 M sodium/potassium phosphate buffer, pH 7.0. A blank reaction mixture containing all of the components except the PPO enzyme was prepared for each test substrate so that enzyme-mediated pigment formation could be distinguished from the non-enzymatic oxidation of the substrate. The test mixtures and their corresponding blanks were covered with Parafilm and incubated at 23° C. for 24 hours. The antiviral activity of each test and blank reaction mixture was determined by measuring its ability to inhibit the infection of cultured human foreskin fibroblasts by
HSV 1. A PPO product was considered to be soluble in aqueous solution when enzymatically formed pigment in the test reaction was present in a clear supernatant at the end of the incubation period. Base-soluble products were pigments that presented as cloudy or turbid suspensions or as precipitates at the end of the incubation, but were transformed into clear solutions by the dropwise addition of 0.1 N NaOH. Table 1 shows the results of our test of 35 potential melanogenic substrates of the PPO enzyme (E.C. 1.10.3.1) from banana (Musa sapientum) skin. -
TABLE 1 Physical Properties and Antiviral Activities of Melanins Prepared by Enzymatic Process. Substrate PPO Solu- Anti- Common Substrate Chemical Sub- bil- HSV-1 Name Name strate ity1, 2 titer3 Dopamine 3,4-dihydroxyphenylamine Y b 20 L-DOPA 3-(3,4-dihydroxyphenyl)-L- Y b 80 alanine L-tryptophan A-aminoindole-3-propionic N — — acid Catechin 2-(3,4-dihydroxyphenyl)- Y b 20 Hydrate 3,4-dihydro-2H-1- benzopyran-3,5,7-triol Pyrocatechol 1,2-benzenediol Y b toxic Chlorogenic 3-(3,4-dihydroxy- N — — acid cinnamovljquinic acid p-Coumaric acid 4-hydroxycinnamic acid N — — Protocatechuric 3,4-dihydroxybenzoic acid Y aq 160 acid Naringenin 4′,5,7-trihydroxyflavanone N — — Tryptamine 3-(2-aminoethyl)indole N — — Serotonin 5-hydroxytryptamine Y aq toxic Syringic acid 4-hydroxy-3,5- N — — dimethoxybenzoic acid Vanillic acid 4-hydroxy-3-methoxy- N — — benzoic acid Kynurenic acid 4-hydroxy-2- N — — quinolinecarboxylic acid Homovanillic 4-hydroxy-3-methoxy- N — — acid phenylacetic acid DOPAC 3,4-dihydroxyphenylacetic Y aq 160 acid Deoxy- 3,4-dihydroxy- Y b 80 epinephrine phenylethylamine Isoproterenol 3,4-dihydroxy-alpha- Y aq toxic [(isopropyl amino )methyl]- benzyl alcohol Norepinephrine 2-amino-I-(3,4- Y b toxic dihydroxyphenyljethanol Epinephrine 3,4-dihydroxy-1-[I- Y aq 80 bitartrate hydroxy-2-(methylamino)- ethvllbenzene Resorcinol 1,3-benzenediol N — — L-Tyrosine B-(p-hydroxyphenyl)- N — — alanine O-Tyrosine B-(p-hydroxyphenyl)- N — — alanine 3-nitro-L-tyrosine N — — Baicalein 5,6,7 trihydroxyflavanone Y b 10 2,3 dihydroxybenzoic acid y/n aq <10 Esculetin 6,7 Dihydroxvcoumarin Y aq 320 2,3,4-trihydroxybenzoic Y aq 20 acid β-resorcylic acid 2,4-dihydroxybenzoic acid N — — Quercetin 2-(3,4-dihydroxyphenyl)- y/n b toxic 3,5,7-trihydroxy-4H-1- benzopyran-4-one Gallic acid 3,4,5-trihydroxybenzoic Y aq 80 acid 2,3,4- Y aq <10 trihydroxybe~dehyde Alizarin 1,2-dihydroxy- Y b toxic anthraquinone 2,3-dihydroxynapthalene Y aq 40 Pyrogallol 1,2,3-trihydroxvbenzene Y aq 80 Caffeic acid 3,4-dihydroxycinnamic Y aq 160 acid 1the test reaction mixture became colored over time and its color intensity exceeded that which developed in the blank reaction mixture. 2aq: product soluble in 0.2M phosphate buffer at pH 7.0; b: product required the addition of strong base to achieve solubility. 3titer values are directly proportional to antiviral potency. These results are relative values and were obtained by making a starting dilution of 1:10 from the synthetic preparation and then preparing serial two-fold dilutions through 1:1280. Therefore, the least amount of activity was <1:10 and the higher the number the greater the activity. The antiviral titer was determined in an in situ ELISA using HSV-1. With each ELISA plate, there was a column of eight wells that have cells but do not have either virus or drug and were used as the negative controls. There was also a column of eight wells with cells infected with HSV-1 but without drug that was used as the positive control. “Toxic” means that the compound was toxic to the cells so that it was not possible to determine any antiviral activity. The toxic effect of compounds to the cells makes the cells appear shrunken, crenated, pycnotic, and irregularly shaped. The cytopathic effect of HSV-1 causes the cells to be enlarged and round. - The results showed that dihydroxyphenyl containing molecules are generally melanogenic at neutral pH in this enzyme-catalyzed process, but that many of the substrates yielded products that were not soluble in aqueous solutions at neutral pH. Furthermore, some of the soluble melanins were toxic to the cultured human cells that were used to test for antiviral activity. Among the soluble, nontoxic melanins, 14 inhibited the infection of cultured human cells by HSV-1. Among this group of compounds, the most potent melanins were produced from benzoic acid (e.g. protocatechuric acid), cinnamic acid (e.g. caffeic acid) and dihydroxycoumarin (e.g. esculetin) substrates.
- The enzyme catalyzed synthesis of antiviral melanins was further tested using a purified PPO (I.U.B.: 1.14.18.1) from Agaricas bisporus (mushroom) as the catalyst. This enzyme was tested for its ability to produce antiviral melanins from 13 dihydroxy phenyl-containing substrates. For this test, 2.0 mg of substrate was added to 1 ml of 0.1 M potassium phosphate, pH 7.0 that contained 0.8 mg (22 catechol oxidase units) of mushroom PPO. Blank reaction mixes containing all ingredients except for the PPO were simultaneously evaluated. Despite the fact that 10 of the 13 substrates were only sparingly soluble, the suspensions of these substrates in the test and blank reaction mixtures were capped with parafilm and incubated in a block heater at 30° centigrade for 45 hours. The final pigmented solutions were centrifuged at 10,000 g and the supernatants were placed in a boiling bath for 20 minutes to inactivate the enzyme. The soluble supernatants containing enzymatically synthesized melanins were active against HSV-1 at the inhibitory titers shown in Table 2.
-
TABLE 2 Physical Properties and Antiviral Activities of Melanins Prepared by Enzymatic Process. Soluble Anti-HSV 1 Soluble Substrate Substrate1 Titer2 Toxicity Product3 Phenol Red n <10 N y Baicalein n <10 N y Quercetin n 320 N y 2,3 Dihydroxynapthalene n 80 Y y Nordihydroguaiuretic acid n 10 N y Gallic acid n 160 Y y Caffeic acid y 1280 N y Alizarin n <10 N y DOPAC y 320 N y Pyrogallol n 160 Y y Catechin n 40 N n Protocatechuric acid y 640 N y Esculetin n 640 N y Dapthnetin n 320 N y 1y: substrate completely soluble in reaction mixture; n: substrate present in reaction mixture as a saturated solution. 2Titer was directly proportional to anti-viral potency. See footnote 3 in Table 1. 3n: product formed a visible precipitate when diluted 1/10 or 1/20 in cell culture media - All but one of these enzymatically synthesized melanin products was soluble in aqueous buffer at a neutral pH. Based on initial studies such as these, 2 substrates, caffeic acid and esculetin, were selected for the purpose of demonstrating a general, scalable process for the production of enzymatically synthesized melanins from precursors containing dihydroxyphenyl substituents.
- Process for the Production of Caffeic Acid Melanin (ES-CAM).
- 150 mg of caffeic acid (3,4-dihydroxy cinnamic acid, Sigma Aldrich, Milwaukee, Wis., catalog No. D11, 080-9) was added to a 150 mL Erlenmeyer flask containing 60 mL of 0.1 M potassium phosphate buffer,
pH 7. - The mixture was stirred for 10 minutes at 23° C. to provide a solution with the pH of 6.73. The pH was adjusted to 7.0 with dilute sodium hydroxide. 60 mg polyphenol oxidase (PPO) (23 units per mg catechol oxidase activity, Worthington Biochemicals Corp. Lakewood N.J., Catalog No. TY) was added and swirled in the flask to dissolve the enzyme. The flask was covered with parafilm and incubated in a block heater for 48 hours at 40° C. The flask was then placed in a boiling water bath for 20 minutes to inactivate and denature the PPO. The mixture was cooled and the pH adjusted to pH 3.5 by adding HCl. The flask was allowed to stand overnight under refrigeration to precipitate the enzymatically synthesized melanin product. This suspension was centrifuged, and the melanin pellet washed 3 times with 24 mL of 0.01 N HCl. The washed pellet was dissolved in 16 ml of 0.2 M sodium bicarbonate. This solution was dialyzed in
SpectraIPor 4 cellophane dialysis tubing (10-14 kDa MWCO, Spectrum Laboratories Inc., Rancho Dominguez, Calif.) against 4×4 L changes of deionized water. The retentate was lyophilized. Enzymatically synthesized melanin product was recovered as a dark brown powder with a dry weight of 128 mg (85% yield). - Process for the Production of Esculetin Melanin (ES-EM).
- 150 mg of esculetin (6,7-dihydroxycoumarin (Sigma-Aldrich, Milwaukee, Wis., catalog No. 24,6573) was added to 60 ml of 0.1 M potassium
phosphate buffer pH 7 in an Erlenmeyer flask and mixed for 10 minutes at 23° C. 60 mg of mushroom PPO was added to this saturated solution and gently swirled in the flask to dissolve the enzyme. The flask was covered with parafilm and incubated at 40° C. for 144 hours. The flask was placed in a boiling water bath, and the enzymatically synthesized melanin product, ES-EM, was isolated by acid precipitation, washing, dialysis, and lyophilization as described for ES-CAM. ES-EM was recovered as an amber colored powder with a dry weight of 116 mg (77% yield). - Physical Properties of Enzymatically Synthesized Melanins Prepared by this Invention.
- ES-CAM and ES-EM prepared by the process described above were polymers that are soluble in water and in aqueous buffer solutions with pH's of 4.5 and above. For comparison purposes, nonenzymatically (chemically) synthesized melanins were prepared by oxidizing aqueous solutions of caffeic acid or esculetin at 40° C. and pH 9.0 for a 144 hours period during which humidified room air was continuously bubbled through the reaction mixtures. The final products were isolated by acid precipitation, dialysis, and lyophilization as described above. HPLC-GPC chromatography of ES-CAM at pH 8.6 (
FIG. 1A ) showed that the product eluted as a single peak with a number average molecular weight of 19.7 kDa. The ultraviolet spectrum of the peak (FIG. 3A ) showed a nearly linear increase in absorbance as the wavelength decreased from 300 to 200 nm, a characteristic spectral feature of natural and enzymatically synthesized melanins. Superimposed on this feature were broad, subtle absorbance maxima at 230, 285, and 320 nm, the last two of which are characteristic of cinnamic acid moieties. Under the same conditions, nonenzymatically synthesized melanin prepared from caffeic acid eluted with a molecular weight of 14.7 kDa (FIG. 1B ). The UV spectrum of this chemically synthesized melanin was similar to that of its enzyme-synthesized counterpart (FIG. 3A ). - The enzymatically synthesized melanin ES-EM eluted from the HPLC-GPC column with a number average molecular weight of 15.4 kDa (
FIG. 2A ). The UV spectrum of this product showed major absorbance peaks at 235 and 360 nm and a subtle peak at 270 nm (FIG. 3B ). Again, these spectral features were superimposed on the characteristic monotonic absorbance change in the 300 to 200 nm range as described above. Under the same analytical conditions, nonenzymatically synthesized esculetin melanin had a similar UV spectrum (FIG. 3B ) but eluted with a molecular weight of 12.9 kDa (FIG. 2B ). Note that for both the caffeic acid and esculetin substrates, the melanins production by enzymatic synthesis had higher molecular weights than their nonenzymatically-synthesized counterparts. - FTIR spectroscopy of ES-CAM and ES-EM, which was performed by McCrone Associates, Inc. (Westmont, Ill.), showed that the enzymatically synthesized melanins ES-CAM and ES-EM demonstrated strong absorption bands in 5 regions of the infrared spectrum: in the 3390 to 3450 cm−1 region; in the 1600 to 1700 cm−1 region; in the 1500 to 1600 cm−1 region; in the 1360 to 1410 cm−1 region; and in the 1220 to 1280 cm−1 region. The broad band at approximately 3400 cm−1 is attributed to OH stretching of phenolic and carboxylic acid groups. The bands in the 1500 to 1700 region are attributed to aromatic C═C bonds and aromatic C═C bonds conjugated with C═O and or COO— groups. The bands in the 1300 to 1400 region are attributed to CH2 groups of aliphatic radicals, CH neighboring to OH and COOH groups, and C═O groups of quinones. The bands in the 1200 to 1300 region are attributed to phenolic C—OH stretching. The absorbance bands for ES-CAM were observed at wavenumbers of 3397, 1616, 1508, 1389, and 1267 cm−1. The absorbance bands for ES-EM were present at wavenumbers of 3409, 1686, 1571, 1397, and 1262 cm−1. The FTIR spectra are similar to those previously reported for certain natural melanins (Savia, V. M. et al., Food Chemistry 2001, 73:177-184; Turick, C. E. Applied and Environmental Microbiology 2002, 68: 2436-2444; Pigment Cell Research 2005, 18: 130-135; and Liu, Y. et al., Photochemistry and Photobiology 2005, 11:135-144) and for melanins chemically synthesized from catecholamines or quinones (Cataldo, F. Polymer International 1998, 46:263-269).
- ES-CAM and ES-EM synthesized by our enzymatic processes were analyzed by MALDI-TOF mass spectrometry by M-Scan Inc. (West Chester, Pa.). High resolution analysis in the positive ion mode using a matrix of Dithranol+AgTFA showed that both ES-CAM and ES-EM had spectra characteristic of polymers with number average molecular weights of approximately 3.6 kDa and 3.3 kDa, respectively. Both enzymatically synthesized melanins had mass spectra that indicated high degrees of polydispersity. Both melanin products contained multiple molecular species (i.e, oligomers) that differed by 24 m/z units. This mass difference is consistent with the presence of oligomers containing multiple intra-chain ring closures and extended polynuclear (graphite-like) structures (Brown, C. E. and Cody, R. B. J. Polymer Sci. Part C: 24,519-528(1986)). Further analysis of ES-EM under different analytical conditions using a more acidic DHB matrix gave a spectrum characterized by multiple clusters of peaks (
FIG. 5 ). The major components of each cluster had m/z ratios of 550.7, 730.7, 912.6, 1092.0, 1271.2, 1451.4, 1629.8, 1807.8, 1991.8, 2170.5, and 2340.5. The incremental difference of 179 amu between the major peaks of each cluster is close to the molecular mass of esculetin (178.15 g/mol), suggesting that ES-EM contains esculetin polymers with different degrees of polymerization. These results also suggest that in aqueous solution, ES-CAM and ES-EM exist as aggregates of low molecular weight oligomers. - Process for Chemical Production of Melanins.
- 18 melanins were prepared from commercially available precursors, obtained from Sigma-Aldrich (St. Louis, Mo.). The melanins are designated as C1 to C18, listed in table 4.
- 15 mg of the precursor was dissolved in 7 mL of 0.2 M sodium carbonate buffer, pH 10.6 in a glass test tube. Then 30 μL of a 5 mg/mL solution of salcomine (N,N′-bis(salicylidine)ethylene diiminocobalt (II) (Sigma Aldrich, catalog No. 274712) in dimethylformamide was added into the solution. The tube was placed in a block heater at 45° C. The outlet of a capillary tubing was inserted at the very bottom of the test tube, the tube was capped, and a continuous stream of humidified room air (flow
rate 25 mL/min) was bubbled through the reaction mixture. At 12 hour intervals, sufficient deionized water was added to the reaction mixture to restore its total volume to 7 mL. After 48 hour, the pigmented reaction mixture was cooled to ambient temperature, transferred to Spectra/Por 6 dialysis tubing (1000 Da MWCO, Spectrum Laboratories Inc., Rancho Dominguez, Calif.) and dialyzed against 4×4 L changes of deionized water. The dialyzed product was lyophilized in a tared vessel, and recovered as a dry solid. The polymer products were recovered at yields ranging from 11% to 89% (median 59%) as shown in Table 4. - The chemical synthesis process was also scaled up by a factor of 10. The reaction mixtures of 150 mg precursor, 70 mL buffer, 300 μL of 5 mg/mL salcomine were incubated in pear flasks for 48 hours at 45° C. with a bubbling stream of air at a flow rate of 125 ml/min. The percent yields were similar to those reported in Table 4 and the weights of the final products were increased by approximately 10-fold.
- Physical Properties of Melanins Prepared by Chemical Synthesis.
- The results of HPLC-GPC chromatography of the chemically synthesized melanin polymers and their ultraviolet spectra are presented in
FIGS. 6 a, 6 b, and 6 c. The number average molecular weight of each compound based on its elution volume relative to those of dextran standards of known molecular weights are presented in Table 4. Eight of the chemically synthesized polymers were analyzed by FTIR (FIGS. 7 a and 7 b). The spectra are similar to those previously obtained for natural and enzymatically synthetic melanins. The differences in the FTIR spectra of ES-CAM and C11 and between the FTIR spectra of ES-EM and C10 illustrate structural differences in polymers made from the same precursors by the two different processes—one enzymatic and one chemical. - Antiviral Activities of the Enzymatically and Chemically Synthesized Melanins.
- The antiviral activities of the enzymatically synthesized melanins ES-CAM and ES-EM are summarized in Tables 3 through 14.
-
TABLE 3 Anti-Viral Potency of ES-CAM and ES-EM (ED50, μg/mL)1. Compound: ES-CAM ES-EM Precursor: Caffeic Acid Esculetin Virus Strain2 HSV-IF 1.00 2.00 Clin 61665 1.00 2.00 15985 (AR) 1.00 2.00 Clin 10301(AR) 1.00 1.00 HSV-2G 0.25 1.00 Clin 23235 0.50 2.00 Clin 27071 0.25 1.00 Clin 16064 (AR) 0.50 1.00 CMV AD169 0.25 1.00 Clin D16 (GR) 0.25 0.50 Clin OBR (GR) 0.12 0.50 HIV BAL strain 0.21 0.036 1The anti-HSV assay was an in situ ELISA performed with minor modifications (Thompson and Dragar, Phytotherapy Research 18: 551-555, 2004). The anti-CMV assay was a plaque reduction assay and was performed with minor modification (Sullivan, V., et.al., Antimicrobial Agents and Chemotherapy 37: 19-25, 1993). 2Clin: virus strain is a primary isolate obtained from an infected human; AR; acyclovir resistant; GR: ganciclovir resistant. - The results in Table 3 show that both compounds have high potencies against
HSV 1, HSV-2, CMV and HIV with ED50's in the range of 0.036 to 2.0 μg/mL. Considering the molecular weights of the enzymatically synthesized melanins in aqueous solution, these new antiviral agents are active at concentrations in the range of 6 to 100 nM. ES-CAM and ES-EM inhibit infections by virus strains that are resistant to typical antiviral medications such as acyclovir and ganciclovir. - The anti-HIV results were determined by the Viral Quality Assurance Laboratory at Rush University directed by James Bremer, Ph.D. The VQA laboratory is responsible for establishing the quality control testing for all AIDS Clinical Trial Group (ATCG) laboratories in the U.S. The results with ES-CAM and ES-EM using a laboratory strain of HIV tested in the VQA laboratory were 0.21 ug/mL and 0.036 ug/mL respectively.
- Therefore, the enzymatically synthesized ES-CAM and ES-EM prepared according to this invention will prevent many different viral infections including HSV and HIV by acting as inhibitors of virus binding and/or virus fusion. Melanins that were nonenzymatically synthesized from caffeic acid and esculetin precursors by spontaneous polymerization at a basic pH typically had maximum anti-HSV 1 potencies (ED50) of ≧4 μg/mL. Hence, the antiviral activities of melanins made by the enzymatic synthesis process described here are 2- to 16-fold greater than those of spontaneous polymerized melanins prepared from the same precursors.
- ED50 values for the enzymatic and chemically synthesized melanins as determined in our laboratory and the Bremer laboratory at Rush University are summarized in Table 4. BAL HIV-1 strain was used in the HIV assay. The cells were exposed to the compounds for 1 hour prior to infection with the BAL HIV-1 strain (200 TCID50/200,000 cells). The cells (200,000 cells per well) were infected overnight and the
next day 100 μL of supernatant was removed and 100 μL of fresh compound media was added to the appropriate wells. Atday day 7, the supernatant was diluted 1:1560 and tested using Perkin-Elmer's HIV-1 p24 kit. -
TABLE 4 Physical Properties and Antiviral Activities of Synthetic Melanins Prepared Enzymatically (Process 1) and Chemically (Process 2). ED50 ED50 Molecular ED50 ED50 hCMV hCMV ED50 ED50 % Mass HSV1 HSV2 [AD169] [D16] HIV HIV Process Cmpd Precursor Recovery (kDa) (ug/mL) (ug/mL) (ug/mL) (ug/mL) (ng/mL) (nM) 1 ESCAM caffeic acid 85 19.7 1 0.25 0.25 0.25 210 10.65 1 ESEM esculetin 77 15.4 2 1 1 0.5 36 2.33 2 C1 pyrogallol 64 8.37 32 16 2.5 2.5 4.16 0.5 2 C2 quercetin dihydrate 75 11.27 16 8 2 1 21.89 1.94 2 C3 daphnetin 63 6.83 128 64 10 10 17.58 2.57 2 C4 2,3 52 5.13 32 16 5 2.5 21.95 4.28 dihydroxynapthalene 2 C5 3,4 60 7.31 32 16 5 5 32.83 4.49 dihydroxybenzoic acid (protocatechuric acid) 2 C6 6,7-dihydroxy-4- 51 7.03 128 32 20 20 39.35 5.6 coumarinyl acetic acid 2 C7 baicalein 11 4.59 128 64 13.72 2.99 2 C8 gallic acid 48 6.45 >128 64 40 40 115.01 17.83 2 C9 3,4 75 15.45 4 4 1 1 17.55 1.14 dihydroxyphenylacetic acid 2 C10 esculetin 73 9.4 16 4 5 2.5 124.67 13.26 2 C11 caffeic acid 77 13.8 8 8 1 1 17.87 1.29 2 C12 catechin 89 80.23 4 2 0.5 0.25 19.12 0.24 2 C13 nordihydroquaiuretic 58 14.97 32 16 5 5 59.39 3.97 acid 2 C14 baicalein hydrate 13 4.88 128 128 10.4 2.13 2 C15 2,3,4 39 6.74 64 16 20 20 8.57 1.27 trihydroxybenzoic acid 2 C16 epinephrine 14 6.44 >128 128 40 20 216.38 33.6 (bitartrate) 2 C17 epinine (2 deoxy 48 99.24 4 4 1 1 138.09 1.39 norepinephrine) 2 C18 2,3,4 45 9.71 32 32 2 2 42.12 4.34 trihydroxybenzaldehyde - Several of the chemically synthesized compounds, in particular C1, C12, C9, C11 and C17 are highly potent inhibitors of HIV infection in vitro, while the enzymatic synthetic products have the highest in vitro potencies for the inhibition of herpes virus infections.
- The enzymatically synthesized melanins ES-CAM and ES-EM and 8 of the chemically synthesize melanins (C1, C2, C4, C9, C11, C12, C15, and C17) were submitted to the National Institute of Allergy and Infectious Diseases (NIAID) Antimicrobial Acquisition and Coordinating Facility (Project Officer Dr. Chris Tseng) to be tested for in vitro activity against 7 Types of herpesviruses; 7 respiratory viruses; 2 orthopoxviruses, and a Biodefense panel of 10 viruses as well as for in vivo activity testing in animal models for herpesviruses, respiratory viruses, and scrapie. The details of the assay protocols used for testing and the investigators that carried out the testing are described on the NIAID website. The results that have been reported to date are presented in Tables 5-14.
- The results reported for anti-HSV-1 (Table 5) anti-HSV-2 (Table 6) activities confirmed those obtained in our own laboratory. Note that the EC50's for 5 of the synthetic melanins were less than that of Acyclovir (ACV), the major current antiviral drug currently used to treat HSV-2 infections in humans. Synthetic melanin C2 was more than 20 times as potent as ACV in this assay.
- The synthetic melanins demonstrate activity toward a number of respiratory viruses (tables 7-11). Especially significant are the high potencies of 4 of our compounds toward Influenzas A (including H5N1) and B. Since the portals of entry of the respiratory viruses and many other clinically important enveloped viruses are the epithelial surfaces of the oral cavity, the nasopharynx, the respiratory tract (and possibly the GI Tract) and the conjunctiva, antiviral prophylaxis or treatment could be delivered by non parenteral application, such as drops, oral solutions, sprays or nebulized droplets. Given the fact that current human antiviral therapies for H5N1 are prohibited from use in poultry because of the risk of the emergence of resistant strains that might be transmitted to humans, our compounds may be especially valuable in that they have a different mechanism of action than the currently available drugs. The synthetic melanins could be used for veterinary applications, while other drugs like the neuraminidase inhibitor, Oseltamivir, could be reserved for human use.
-
TABLE 5 Anti-HSV-1 Potency in HFF cells (μg/mL). Cell ACV ACV GCV Cmpds Assay Line EC50 EC90 CC50 SI EC50 CC50 CC50 C1 CPE HFF 8.9 45 >100 >11 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells C2 CPE HFF 2.2 13 >100 >45 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells C4 CPE HFF >100 >100 >100 0 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells C9 CPE HFF 2.6 >100 >100 >38 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells C11 CPE HFF 1.9 3.4 >100 >53 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells C12 CPE HFF 2.4 4 >100 >42 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells C15 CPE HFF 25.6 >100 >100 >3.9 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells C17 CPE HFF 1.8 4.2 >100 >56 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells ESCAM CPE HFF 1.8 3.7 >100 >56 1.1 Cells Tox- Sta- >100 >100 >100 NRU tion- ary HFF Cells ESEM CPE HFF 1.4 2.6 >100 >71.4 1.1 Cells Tox- Sta- NRU tion- ary HFF >100 >100 >100 Cells -
TABLE 6 Anti-HSV-2 Potency in HFF cells (μg/mL). ACV ACV GCV Cmpds Assay Cell Line EC50 EC90 CC50 SI EC50 CC50 CC50 C1 CPE HFF Cells 0.11 10.6 >100 >909 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells C2 CPE HFF Cells 0.06 2.4 >100 >1666 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells C4 CPE HFF Cells >100 >100 >100 0 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells C9 CPE HFF Cells 0.1 >100 >100 >1000 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells C11 CPE HFF Cells 0.8 >100 >100 >125 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells C12 CPE HFF Cells 0.3 14 >100 >333 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells C15 CPE HFF Cells >100 >100 >100 0 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells C17 CPE HFF Cells 2.8 16 >100 >36 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells ESCAM CPE HFF Cells 4.2 20 >100 >24 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells ESEM CPE HFF Cells 11.4 31 >100 >8.7 1.4 Tox- Stationary >100 >100 >100 NRU HFF Cells -
TABLE 7 Anti-viral Potency (μg/mL). EC50's Flu A Flu A Flu A Yellow CMPD H1N1 H3N2 H5N1 Flu B SARS Vaccinia Cowpox Fever C1 32 21 25 32 69 >100 >100 >100 C2 73 56 32 32 >100 90.2 72.7 >100 C4 56 56 5.6 32 13 >100 75.8 >100 C9 46 35 22 32 57 63.1 35.1 >100 C11 32 56 8.3 32 32 80.3 >100 >100 C12 2.5 3.6 * * 27 10.4 26.3 >100 C15 32 >100 36 >100 >100 >100 >100 >100 C17 19 4.8 * 32 25 11.7 26.8 >100 ESCAM 11 3.2 * * 25 17.5 35.8 >100 ESEM 2.5 * * 5 32 16.9 27.6 >100 * Compound demonstrated moderate to high activity in screening assay. See additional test results in Table 8, 9, 10, and 11. -
TABLE 8 Anti-viral Potency of C12. Trial Virus Virus Strain Assay No. EC50 EC90 IC50 SI Flu A Duck/MN/ Neutral 1 0.84 >100 >120 (H5N1) 1525/81 Red Visual 1 0.75 100 130 Virus 2 3.2 31 Yield Visual- 2 0.75 100 130 CONF Vietnam/ Neutral 1 3 >100 >33 1203/2004H Red Visual 1 3.2 32 10 Neutral 2 0.83 >100 >120 Red Visual 2 0.59 53 90 Virus 3 6.2 8.5 Yield Visual- 3 0.59 53 90 CONF Flu B Malaysia/ Neutral 1 4.9 >100 >20 2506/2004 Red Visual 1 4.6 32 7 Neutral 2 2.8 >100 >36 Red Visual 2 2 >100 >50 Virus 3 30 >3.3 Yield Visual- 3 2 >100 >50 CONF (Cell line: MDCK. Vehicle: Sponsor Buffer. Unit: μg/mL). -
TABLE 9 Anti-viral Potency of C17. Trial Virus Virus Strain Assay No. EC50 EC90 IC50 SI Flu A Duck/MN/1525/81 Neutral 1 2.3 >100 >43 (H5N1) Red Visual 1 2.8 >100 >36 Virus 2 6.3 >16 Yield Visual- 2 2.8 >100 >36 CONF Vietnam/1203/ 2004H Neutral 1 6.2 >100 >16 Red Visual 1 0.83 100 120 (Cell line: MDCK. Vehicle: Sponsor Buffer. Unit: μg/mL). -
TABLE 10 Anti-viral Potency of ES-EM. Trial Virus Virus Strain Assay No. EC50 EC90 IC50 SI Flu A Duck/MN/ Neutral 1 0.23 96 420 (H5NI) 1525/81 Red Visual 1 0.19 53 280 Virus 2 1.9 28 Yield Visual- 2 0.19 53 280 CONF Vietnam/1203/ Neutral 1 3.1 34 11 2004H Red Visual 1 1.8 46 26 Neutral 2 0.51 >100 >200 Red Visual 2 0.21 65 310 Virus 3 1.5 43 Yield Visual- 3 0.21 65 310 CONF (Cell line: MDCK. Vehicle: Sponsor Buffer. Unit: μg/mL). -
TABLE 11 Anti-viral Potency of ES-CAM. Trial Virus Vehicle Assay No. EC50 EC90 IC50 SI Flu A DMSO Neutral 2 9.1 >100 >11 (H3N2) Red Visual 2 6.8 >100 >15 Virus 3 14.5 6.9 Yield Visual- 3 6.8 >100 >15 CONF Flu A Sponsor Neutral 1 4.2 50 12 (H5N1) buffer Red Visual 1 4.3 >100 >23 Virus 2 4.4 >23 Yield Visual- 2 4.3 >100 >23 CONF Neutral 2 3.1 >100 >32 Red Visual 2 1.8 53 29 Flu B Neutral 1 3.4 79 23 Red Visual 1 3.2 40 13 Neutral 2 5.9 >100 >17 Red Visual 2 6 >100 >17 Virus 3 7.2 >14 Yield Visual- 3 6 >100 >17 CONF (Cell line: MDCK; Unit: μg/mL). -
TABLE 12 Anti-viral Potency. EC50's (ug/mL) Rift Dengue CMPD Adeno PIV Rhino RSV A Valley Tacaribe C C1 >100 >100 >100 >100 >100 >100 nt C2 >100 >100 >100 >100 >100 >100 33 C4 >100 >100 >100 >100 >100 >100 26 C9 >100 >100 >100 >100 42 >100 >100 C11 >100 >100 >100 >100 64 >100 >100 C12 >100 >100 >100 32 30 >100 >100 C15 >100 >100 >100 >100 >100 >100 nt C17 >100 >100 >100 38 28 nt nt ESCAM >100 >100 >100 41 32 45 nt ESEM >100 >100 >100 >100 30 41 nt nt: Compound not tested - The potency and the cytotoxicity of melanins in the present invention were also evaluated for other viruses (VZV, EBV) in various cell lines, shown in table 13 and 14. ESEM, C2, C9 and C12 have high potencies against VZV with EC50's in the range of 0.03 to 3.9 μg/mL. The potencies of ES-EM and C12 exceeded that of Acyclovir (AVC), the positive control that was used in the assay. Cytotoxicity study showed all of these four melanins have CC50's larger than 100 μg/mL. None of the compounds tested had significant in vitro activity against EBV.
-
TABLE 13 Anti-Viral Potency in HFF cells (μg/mL). VZV(Varicella Zoster Virus) ACV Cmpd EC50 EC90 CC50 SI EC50 ESCAM nt nt nt nt 0.06 ESEM <0.0300 <0.0300 >100 >3333 0.06 C1 36 49.3 >100 >2.8 0.17 C2 3.9 31.7 >100 >26 0.17 C4 10 43.4 >100 >10 0.17 C9 3.7 >100 >100 >27 0.17 C11 64.8 95.7 >100 >1.5 0.06 C12 <0.0300 <0.0300 >100 >3333 0.06 C17 nt nt nt nt 0.06 nt: Compound not tested. -
TABLE 14 Anti-Viral Potency in Akata cells (μg/mL). EBV (Epstein-Barr Virus) Cmpd EC50 EC90 CC50 SI ACV EC50 ESCAM 98.3 >100 >100 >1 2.7 ESEM >100 >100 >100 0 2.7 C1 >100 >100 >100 0 0.7 C2 >100 >100 >100 0 0.7 C4 >100 >100 >100 0 0.7 C9 >20 >20 >20 0 0.7 C11 >20 >20 >20 0 0.7 C12 >100 >100 >100 0 0.7 C15 >100 >100 >100 0 0.7 C17 >100 >100 >100 0 0.7 - Inhibition of Lysozyme Fibrillation by Enzymatically and Chemically Synthesized Melanins.
- The inhibition of lysozyme fibrillation in vitro was tested with synthetic and natural melanins.
- Solutions of lysozyme (hen egg white, 20 mg/mL) were incubated in 20 mM glycine-HCl buffer at 58° C. for 8 days in the presence of one of the melanins. The incubation mixtures were sampled repeatedly and the kinetics of lysozyme fibrillation were evaluated by Thioflavin T (Tht) fluorescence, native PAGE, and fluorescence and dark field microscopy. Compounds C11, ES-EM, and C12 (
FIG. 8 ) inhibited the development of THT fluorescence to levels that were 16%, 42%, and 61%, respectively, of untreated control mixtures. PAGE analysis of the time points taken during the incubation containing C11 showed that this compound decreased the generation of lysozyme oligomers during the first 48 hours of incubation and delayed the progression of the assembly of lysozyme monomers and oligomers into lysozyme fibers and aggregates. The data suggests that synthetic melanins may be of therapeutic value as fibrillogenesis inhibitors. - It is intended that the foregoing detailed description be regarded as illustrative rather than limiting, and that it be understood that it is the following claims, including all equivalents, that are intended to define the spirit and scope of this invention.
Claims (34)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/809,369 US8673983B2 (en) | 2007-12-21 | 2008-12-22 | Melanins synthesized chemically or via enzyme catalysis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US894807P | 2007-12-21 | 2007-12-21 | |
US61008948 | 2007-12-21 | ||
US12/809,369 US8673983B2 (en) | 2007-12-21 | 2008-12-22 | Melanins synthesized chemically or via enzyme catalysis |
PCT/US2008/088004 WO2009082735A1 (en) | 2007-12-21 | 2008-12-22 | Melanins synthesized chemically or via enzyme catalysis |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110230562A1 true US20110230562A1 (en) | 2011-09-22 |
US8673983B2 US8673983B2 (en) | 2014-03-18 |
Family
ID=40801578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/809,369 Expired - Fee Related US8673983B2 (en) | 2007-12-21 | 2008-12-22 | Melanins synthesized chemically or via enzyme catalysis |
Country Status (2)
Country | Link |
---|---|
US (1) | US8673983B2 (en) |
WO (1) | WO2009082735A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472818A (en) * | 2020-11-16 | 2021-03-12 | 安徽农业大学 | Nano material using modified natural melanin as carrier, and preparation method and application thereof |
RU2747018C1 (en) * | 2020-10-14 | 2021-04-23 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере зашиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Sars-cov-2 coronavirus replication inhibitor based on melanin from inonotus obliquus fungus |
CN116919886A (en) * | 2023-07-21 | 2023-10-24 | 中国海洋大学 | Injectable photo-thermal hydrogel based on black pigment, and preparation method and application thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10702571B2 (en) | 2015-12-03 | 2020-07-07 | The University Of North Carolina At Pembroke | Materials for cathepsin B enhancement and methods of use |
CN110115712A (en) * | 2019-07-04 | 2019-08-13 | 兰州大学 | Activator that is a kind of while activating oxidative phosphorylation access and inhibition glycolytic pathway and its application |
CN113440520A (en) * | 2021-04-12 | 2021-09-28 | 桂林医学院 | Application of esculetin derivative in preparation of anti-hepatitis B virus medicine |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057325A (en) * | 1990-03-20 | 1991-10-15 | Vanderbilt University | Method of inhibiting replication of HIV with water-soluble melanins |
US5225435A (en) * | 1990-05-18 | 1993-07-06 | Yale University | Soluble melanin |
US5628799A (en) * | 1991-09-26 | 1997-05-13 | Clairol Incorporated | Hair dying methods and kits which contain a dopa species, reactive direct dye, and a ferricyanide oxidant |
US5631151A (en) * | 1988-10-03 | 1997-05-20 | Biosource Technologies, Inc. | Melanin production by transformed organisms |
US5817631A (en) * | 1988-09-13 | 1998-10-06 | Biosource Technologies, Inc. | Therapeutic uses of melanin |
US6303106B1 (en) * | 1995-12-07 | 2001-10-16 | Zylepsis Limited | Allomelanin production |
US6399046B1 (en) * | 1998-06-20 | 2002-06-04 | Beiersdorf Ag | Use of a content of catechins or a content of green tea extract in cosmetic preparations for tanning the skin |
US6440691B1 (en) * | 1997-02-06 | 2002-08-27 | Large Scale Biology Corporation | Melanins with improved ability to inhibit HIV replication |
WO2005021714A2 (en) * | 2003-08-11 | 2005-03-10 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
US20070166255A1 (en) * | 2004-11-22 | 2007-07-19 | Gupta Shyam K | Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition |
-
2008
- 2008-12-22 WO PCT/US2008/088004 patent/WO2009082735A1/en active Application Filing
- 2008-12-22 US US12/809,369 patent/US8673983B2/en not_active Expired - Fee Related
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817631A (en) * | 1988-09-13 | 1998-10-06 | Biosource Technologies, Inc. | Therapeutic uses of melanin |
US5631151A (en) * | 1988-10-03 | 1997-05-20 | Biosource Technologies, Inc. | Melanin production by transformed organisms |
US5814495A (en) * | 1988-10-03 | 1998-09-29 | Biosource Technologies, Inc. | Melanin production by streptomyces |
US5837505A (en) * | 1988-10-03 | 1998-11-17 | Biosource Technologies, Inc. | Melanin production from transformed escherichia coli |
US5057325A (en) * | 1990-03-20 | 1991-10-15 | Vanderbilt University | Method of inhibiting replication of HIV with water-soluble melanins |
US5225435A (en) * | 1990-05-18 | 1993-07-06 | Yale University | Soluble melanin |
US5628799A (en) * | 1991-09-26 | 1997-05-13 | Clairol Incorporated | Hair dying methods and kits which contain a dopa species, reactive direct dye, and a ferricyanide oxidant |
US6303106B1 (en) * | 1995-12-07 | 2001-10-16 | Zylepsis Limited | Allomelanin production |
US6440691B1 (en) * | 1997-02-06 | 2002-08-27 | Large Scale Biology Corporation | Melanins with improved ability to inhibit HIV replication |
US6399046B1 (en) * | 1998-06-20 | 2002-06-04 | Beiersdorf Ag | Use of a content of catechins or a content of green tea extract in cosmetic preparations for tanning the skin |
WO2005021714A2 (en) * | 2003-08-11 | 2005-03-10 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
US20070166255A1 (en) * | 2004-11-22 | 2007-07-19 | Gupta Shyam K | Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2747018C1 (en) * | 2020-10-14 | 2021-04-23 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере зашиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Sars-cov-2 coronavirus replication inhibitor based on melanin from inonotus obliquus fungus |
CN112472818A (en) * | 2020-11-16 | 2021-03-12 | 安徽农业大学 | Nano material using modified natural melanin as carrier, and preparation method and application thereof |
CN116919886A (en) * | 2023-07-21 | 2023-10-24 | 中国海洋大学 | Injectable photo-thermal hydrogel based on black pigment, and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US8673983B2 (en) | 2014-03-18 |
WO2009082735A1 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8673983B2 (en) | Melanins synthesized chemically or via enzyme catalysis | |
AU660631B2 (en) | Proanthocyanidin polymers having antiviral activity and methods of obtaining same | |
US20150166476A1 (en) | Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta | |
EP3380120B1 (en) | Immunostimulatory compositions | |
US20130296613A1 (en) | Process for production of hydroxystilbene derivative having physiological activity | |
US20140288334A1 (en) | Novel resveratrol polymerization compound or pharmaceutically acceptable salt thereof | |
US20090192217A1 (en) | Method and composition for treating acne using lignan compounds | |
WO2016039229A1 (en) | Antifungal composition comprising antifungal peptide and terpene alcohol | |
Nemoto et al. | Synthesis of highly water-soluble fibrate derivatives via BGLation | |
WO2003064617A2 (en) | Pestalotiopsis microsporia isolates and compounds derived therefrom | |
JP2015214501A (en) | INHIBITOR FOR VIRUS INTRACELLULAR GROWTH, Mn-SOD ACTIVATOR, AND ANTIVIRAL DRUG | |
KR101623553B1 (en) | Chlorin e6 for the treatment, prevention or improvement of acne | |
KR20170038719A (en) | Use of resveratrol derivatives for preventing the skin aging | |
KR20190114900A (en) | Cosmetic composition for improving skin barrier function | |
WO2009102083A1 (en) | Novel clitocybin derivatives, preparation method thereof and composition containing the extract of clitocybe aurantiaca kctc 11143bp or the novel clitocybin derivatives for prevention of aging as an active ingredient | |
WO2020138023A1 (en) | Agent for inhibiting reduction in decomposition of denatured elastin, agent for maintaining normal elastin fibers, agent for inhibiting formation of elastin-elafine composite, and screening method for substance having elastin-elafine composite formation inhibitory effect | |
RU2800446C1 (en) | Water-soluble pigment melanin from the basidiomycete inonotus obliquus with antiviral activity | |
KR20190074538A (en) | A composition for preventing the skin aging comprising Pullulan-Retinoid complex | |
KR20190004991A (en) | Composition for skin whitening | |
WO2017004215A1 (en) | Anti-trypanosomal compounds and methods | |
US20100172937A1 (en) | Enveloped virus neutralizing compounds | |
WO2023131829A1 (en) | A formulation for treatment of pigmentary disorders | |
JP2004091446A (en) | Anti-influenza virus agent | |
JP5672962B2 (en) | Anti-cancer agent, lipase inhibitor, anti-obesity agent, tyrosinase inhibitor and whitening agent containing 4-vinylphenol polymerized compound or pharmaceutically acceptable salt thereof | |
AU2011324809A1 (en) | Novel self-assembling polyphenol-quinonoid polymer derivatives and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE UNIVERSITY OF CHICAGO, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOLMES, EARLE W.;THOMPSON, KENNETH;SIGNING DATES FROM 20100615 TO 20100616;REEL/FRAME:024565/0485 |
|
AS | Assignment |
Owner name: THE UNIVERSITY OF CHICAGO, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THOMPSON, KENNETH;REEL/FRAME:025181/0286 Effective date: 20100616 Owner name: LOYOLA UNIVERSITY CHICAGO, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOLMES, EARLE;REEL/FRAME:025181/0236 Effective date: 20100615 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220318 |